0001114936false--09-30Q12026250000000114785005114785005falsefalsefalsefalse00025000000000011149362025-10-012025-12-310001114936umewf:FordMooreMemberus-gaap:SubsequentEventMember2026-01-190001114936umewf:MichaelLeeCEODirectorMemberus-gaap:SubsequentEventMember2026-01-190001114936us-gaap:SubsequentEventMember2026-01-190001114936umewf:ConcentrationOfSupplierMember2025-10-012025-12-310001114936country:CNumewf:ConcentrationOfGeographicMember2025-10-012025-12-310001114936country:USumewf:ConcentrationOfGeographicMember2024-10-012024-12-310001114936umewf:ConcentrationOfCustomersAndVendorsMemberumewf:OneVendorMember2025-10-012025-12-310001114936umewf:FirstScionInvestmentsLimitedMember2025-09-300001114936umewf:FirstScionInvestmentsLimitedMember2025-12-310001114936umewf:FordMooreDirectorMember2025-09-300001114936umewf:FordMooreDirectorMember2025-12-310001114936umewf:MichaelLeeCEODirectorMember2025-09-300001114936umewf:MichaelLeeCEODirectorMember2025-12-3100011149362024-10-012025-09-300001114936umewf:DagolaHongKongLimitedMember2025-10-012025-12-310001114936umewf:GuangzhouDuokanglongSpecialMedicalNutritionTechnologyCoLtdMember2025-10-012025-12-310001114936umewf:DagolaIncMember2025-10-012025-12-310001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001114936us-gaap:RetainedEarningsMember2025-12-310001114936us-gaap:AdditionalPaidInCapitalMember2025-12-310001114936us-gaap:CommonStockMember2025-12-310001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-10-012025-12-310001114936us-gaap:RetainedEarningsMember2025-10-012025-12-310001114936us-gaap:AdditionalPaidInCapitalMember2025-10-012025-12-310001114936us-gaap:CommonStockMember2025-10-012025-12-310001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001114936us-gaap:RetainedEarningsMember2025-09-300001114936us-gaap:AdditionalPaidInCapitalMember2025-09-300001114936us-gaap:CommonStockMember2025-09-3000011149362024-12-310001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001114936us-gaap:RetainedEarningsMember2024-12-310001114936us-gaap:AdditionalPaidInCapitalMember2024-12-310001114936us-gaap:CommonStockMember2024-12-310001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310001114936us-gaap:RetainedEarningsMember2024-10-012024-12-310001114936us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001114936us-gaap:CommonStockMember2024-10-012024-12-3100011149362024-09-300001114936us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001114936us-gaap:RetainedEarningsMember2024-09-300001114936us-gaap:AdditionalPaidInCapitalMember2024-09-300001114936us-gaap:CommonStockMember2024-09-3000011149362024-10-012024-12-3100011149362025-09-3000011149362025-12-3100011149362026-02-19iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~x Quarterly~~☒ ~~Report~~QUARTERLY ~~Pursuant~~REPORT ToPURSUANT ~~Section~~TO SECTION 13 orOR 15(d) ofOF ~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934.

For the quarterly period ended: December 31, ~~2012~~2025

ORor

~~o Transition~~☐ ~~Report~~TRANSITION ~~Pursuant~~REPORT ToUNDER ~~Section~~SECTION 13 orOR 15(d) ofOF ~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934.

For the transition period from~~:________to_________~~ __________ to _______

Commission File Number: 000-~~030813~~30813

~~AlphaRx,~~UMeWorld Inc. (Exact name of registrant as specified in its charter)

(Name of Small Business Issuer in its Charter)

Delaware

61-2299084

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

Delaware		98-0416123
66 West Flagler Street, 9th Floor, Miami, Florida		33130
(State or other jurisdiction of incorporated or organization)		(I.R.S. Employer Identification No.)
(Address of principal executive offices)		(Zip Code)

~~31/F,~~(786) ~~Tower~~791 ~~One, Times Square~~0483

1(Registrant’s ~~Matheson~~telephone ~~Street~~number, ~~Causeway~~including ~~Bay,~~area ~~Hong Kong~~code)

~~(Address~~Former ofname: ~~principal~~UMeWorld ~~executive offices)~~Limited

~~Registrant's~~(Former ~~telephone~~name, ~~number~~former address, ~~including~~and ~~area~~former ~~code:~~fiscal ~~(852)~~year, ~~2824-8716~~if changed since last report)

~~Indicate~~Securities byregistered ~~check~~pursuant ~~mark whether the registrant (1) has filed all reports required~~ to ~~be filed by~~ Section ~~13 or 15~~12(db) of the ~~Securities Exchange~~ Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o:

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No x

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	UMEW	OTC Markets Group, Inc. (OTCID)

Indicate by check mark whether the registrant is(1) ahas ~~large~~filed ~~accelerated~~all ~~filer,~~reports anrequired ~~accelerated~~to ~~filer,~~be afiled ~~non-accelerated~~by ~~filer,~~Section 13 or a15(d) ~~smaller~~of ~~reporting~~the ~~company.~~Securities ~~See~~Exchange Act of 1934 during the ~~definitions~~preceding of12 ~~“large~~months ~~accelerated~~(or ~~filer”,~~for ~~“accelerated~~such ~~filer”~~shorter period that the registrant was required to file such reports), and ~~“smaller~~(2) ~~reporting~~has ~~company”~~been insubject ~~rule~~to ~~12b-2~~such offiling requirements for the ~~Exchange~~past ~~Act~~90 days. ☒ Yes ☐ No

~~Large~~Indicate ~~accelerated~~by ~~filer~~check omark ~~Accelerated~~whether ~~filer~~the oregistrant ~~Non~~has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-~~accelerated~~T ~~filer~~(§ o232.405 of this chapter) during the preceding 12 months (Door ~~not~~for ~~check~~such ifshorter aperiod ~~smaller~~that ~~reporting~~the ~~company)~~registrant ~~Smaller~~was ~~reporting~~required ~~company~~to xsubmit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a ~~shell~~large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, ~~(as~~or ~~defined~~an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act). ~~Yes o No x~~

~~The~~Large ~~number~~accelerated offiler ~~outstanding~~☐ ~~shares~~Accelerated offiler ~~registrant's~~☐ ~~Common~~Non-accelerated ~~Stock~~Filer on☒ ~~February~~Smaller ~~22,~~reporting ~~2013~~company ~~was~~☒ ~~89,036,000.~~Emerging growth company ☐

~~ALPHARX~~If an emerging growth company, ~~INC~~indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~FORM~~Indicate 10by check mark whether the registrant is a shell company (as defined in Rule 12b-Q2 of the Exchange Act) ☐ Yes ☒ No

~~December~~Indicate 31the number of shares outstanding of each of the issuer’s classes of common stock, ~~2012~~as of the latest practicable date.

Class	Outstanding at February 19, 2026
Common Stock, $0.0001 par value	115,599,593

TABLE OF CONTENTS

Part I. Financial Information
		Page
Item 1. Financial Statements.
PART I	FINANCIAL INFORMATION	3
	Unaudited Interim Consolidated Balance Sheets as of December 31, 2012 and September 30, 2012 (Audited)	3
ITEM 1.	UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:	3
	Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss for the three months ended December 31, 2012 and 2011	4
	Unaudited Condensed Consolidated Balance Sheets	3
	Unaudited Interim Consolidated Statements of Changes in Shareholders’ Deficit as of December 31, 2012 and September 30, 2012	5
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss	4
	Unaudited Interim Consolidated Statements of Cash Flow for the periods ended December 31, 2012 and 2011	6
	Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity	5
	Condensed Notes to Unaudited Interim Consolidated Financial Statements	7-13
	Unaudited Condensed Consolidated Statements of Cash Flows	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	14-17
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	17
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16
Item 4.	Controls and Procedures.	18-19
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	18
Part II. Other Information
ITEM 4.	CONTROLS AND PROCEDURES	19
Item 1.	Legal Proceedings.	20
PART II	OTHER INFORMATION	20
Item 1A.	Risk Factors.	20-28
ITEM 1	LEGAL PROCEEDINGS	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	29
ITEM 1A	RISK FACTORS
Item 3.	Defaults Upon Senior Securities.	29
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	20
Item 4.	Mine Safety Disclosures	29
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	20
Item 5.	Other Information	29
ITEM 4	MINE SAFETY DISCLOSURES	20
Item 6.	Exhibits	30
ITEM 5	OTHER INFORMATION	20
Signatures		31
ITEM 6	EXHIBITS	20
Certifications
	SIGNATURES	21

2 Table of Contents

PART I. - FINANCIAL INFORMATION

~~ITEM~~Item 1. ~~FINANCIAL~~Financial ~~STATEMENTS.~~Statements

~~ALPHARx,~~UMEWORLD INC.

~~INTERIM~~CONDENSED CONSOLIDATED BALANCE SHEETS

~~AS AT DECEMBER 31, 2012 AND SEPTEMBER 30, 2012~~(UNAUDITED)

(~~All~~Currency ~~amounts~~expressed in USUnited States Dollars (“US$”), except for number of shares)

	December 31 2012			September 30 2012
	As of
	(Unaudited)			(Audited)
	December 31,2025(Unaudited)			September 30,2025(Audited)
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	55,741		$	4,342
Cash	$	60,904		$	154,353
Accounts Receivable		259,446			108,982
Deposit		3,610			1,130
Deposit		19,425,347			19,425,347
Prepayment		1,762			514
Deferred Financing Cost		20,000			20,000
Accounts Receivable		62			1,002
Prepayment		6,768			2,505
Inventory		1,682,509			13,410
TOTAL CURRENT ASSETS		191,~~767~~748,~~302~~847			19170,~~561,176~~409
NON-CURRENT ASSETS
TOTAL ASSETS	$	1,748,847		$	170,409
Loan Receivable		1,587,475			1,574,654
LIABILITIES AND STOCKHOLDERS’ DEFICIT
TOTAL ASSETS		21,354,777			21,135,830
CURRENT LIABILITIES
Accounts Payable and Accrued Liabilities		557,810			535,594
Accounts payable		1,670,243			2,395
TOTAL CURRENT LIABILITIES		557,810			535,594
Due to related parties		329,863			279,369
NON-CURRENT LIABILITIES
Accrued liabilities and other payables		211,340			212,556
Notes Payable (Note 3)		934,438			995,912
TOTAL CURRENT LIABILITIES		2,211,446			494,320
TOTAL LIABILITIES	$	12,~~492~~211,~~248~~446		$	1494,~~531,506~~320
STOCKHOLDERS’ DEFICIENCY
STOCKHOLDERS’ DEFICIT
Common Stock: $ 0.0001 par value,
Ordinary shares: $ 0.0001 par value;
Authorized: 250,000,000 shares; Issued and outstanding
Authorized: 250,000,000 shares; Issued and outstanding: 114,785,005 shares as of September 30, 2025 and December 31, 2025		11,479			11,479
September 30, December 31, 2012: 89,036,000 (Notes 5-7)		8,904			8,904
Additional paid-in capital		31,594,254			31,594,254
Additional paid-in capital		38,568,360			38,568,360
Accumulated other comprehensive income		39			-
Deficit		(18,873,680	)		(19,122,924	)
Accumulated deficit		(32,068,371	)		(31,929,644	)
Accumulated Other Comprehensive Loss		(1,476	)		(5,518	)
Total stockholders’ deficit		(462,599	)		(323,911	)
Non-controlling Interest		160,421			155,502
TOTAL LIABILITES AND STOCKHOLDERS’ DEFICIT	$	1,748,847		$	170,409
TOTAL STOCKHOLDERS’ EQUITY/ (DEFICIENCY)		19,862,529			19,604,324
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY/DEFICIENCY	$	21,354,777		$	21,135,830

3 The accompanying notes are an integral part of these consolidated financial statements.

~~ALPHARx,~~3 ~~INC.~~Table of Contents

~~INTERIM~~UMEWORLD ~~CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS~~INC.

~~FOR~~CONDENSED ~~THE~~CONSOLIDATED ~~THREE~~STATEMENTS ~~MONTHS~~OF ~~ENDED~~OPERATIONS ~~December~~AND ~~31,~~COMPREHENSIVE ~~2012~~LOSS ~~AND 2011~~

(UNAUDITED)

(~~All~~Currency ~~amounts~~expressed in USUnited States Dollars (“US$”), except for number of shares)

	3 months ended December 31, 2012			3 months ended December 31, 2011
	For the three months endedDecember 31,
	(Unaudited)			(Unaudited)
	2025			2024
License Fees and Royalties	$	370,329		$	35,683
REVENUE	$	147,455		$	195
Total Revenues		370,329			35,683
Cost of revenues		(142,913	)		(2,583	)
General and Administrative Expenses		96,757			90,182
GROSS INCOME (LOSS)		4,542			(2,388	)
Depreciation		0			654
OPERATING EXPENSES
Gain/(Loss) from Operations		273,572			(55,153	)
Selling, general and administrative expenses		143,296			12,322
OTHER INCOME
TOTAL OPERATING EXPENSES		143,296			12,322
Other Income		3,531			0
LOSS FROM CONTINUING OPERATIONS		(138,754	)		(14,710	)
Interest Income		444			0
OTHER INCOME (EXPENSE)
OTHER EXPENSES
Other income		27			-
Interest Expense, net		24,395			24,013
TOTAL OTHER INCOME, NET		27			-
Gain/(Loss) before Income Taxes		253,152			(79,166	)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		(138,727	)		(14,710	)
Income Tax		-			-
NET LOSS FROM CONTINUING OPERATIONS		(138,727	)		(14,710	)
Net Gain/(Loss)		253,152			(79,166	)
Net loss from discontinued operations, net of tax		-			-
Net Income/(Loss) attributable to Non-controlling interests		(3,908	)		3,893
NET LOSS	$	(138,727	)	$	(14,710	)
Net Gain/(Loss) attributable to AlphaRx Inc. Stockholders		249,244			(75,273	)
Comprehensive loss:
Comprehensive Loss
Net loss	$	(138,727	)	$	(14,710	)
Net Gain/(Loss)		253,152			(79,166	)
Foreign currency translation (loss) income		-			-
Translation Adjustment		5,053			2,608
Total comprehensive loss	$	(138,727	)	$	(14,710	)
Comprehensive Gain/(Loss)		258,205			(76,558	)
Loss per share:
Less: Comprehensive Loss Attributable to Non-Controlling Interests		(1,011	)		(522	)
Net loss from continuing operations per share of ordinary share - basic and diluted	$	(0.00	)	$	(0.00	)
Comprehensive Gain/(Loss) Attributable to AlphaRx Inc. Stockholders		257,194			(77,080	)
Net loss from discontinued operations per share of ordinary share – basic and diluted	$	(0.00	)	$	(0.00	)
Per Share Data
Weighted average number of ordinary shares outstanding:
Net Loss Per Share, basic and diluted	$	0.0029		$	(0.001	)
Basic and diluted		114,785,005			111,785,005
Weighted Average Number of Common Shares Outstanding		89,036,000			95,935,047

4 The accompanying notes are an integral part of these consolidated financial statements.

~~ALPHARx,~~4 ~~INC.~~Table of Contents

~~INTERIM~~UMEWORLD ~~CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY~~INC.

ASCONDENSED OFCONSOLIDATED ~~DECEMBER~~STATEMENTS ~~31,~~OF ~~2012~~CHANGES ~~AND~~IN ~~SEPTEMBER~~STOCKHOLDERS’ ~~2012~~DEFICIT

(UNAUDITED)

(~~All~~Currency ~~amounts~~expressed in USUnited States Dollars (“US$”), except for number of shares)

	Common Stock						Additional			Accumulated Other						Total AlphaRx Inc.			Non-			Total
	Number of Shares			Amount			Paid in Capital			Comprehensive Loss			(Deficiency)			Stockholders’ Deficiency			controlling Interest			Gain/(Deficiency)
Balance as of September 30, 2011		98,935,047		$	9,594		$	17,593,112		$	(5,265	)	$	(19,045,635	)	$	(1,448,194	)	$	171,169		$	(1,277,025	)
Warrants issued for Private Placement								6,558									6,558						6,558
Stock issued for Private Placement		300,000			30			14,970									15,000						15,000
Stock cancelled for settlement		(1,060,000	)		(106	)		(52,894	)								(53,000	)					(53,000	)
Reverse Split		(76,139,047	)		(7,614	)		7,614									-						0
Stock Issued for Acquisition		70,000,000			7,000			20,999,000									21,006,000						21,006,000
Foreign Currency Translation											(253	)					(253	)		(63	)		(316	)
Non-controlling interest																				(15,604	)		(15,604	)
Net Loss for the period														(77,289	)		(77,289	)					(77,289	)
Balance as of September 30, 2012		89,036,000		$	8,904		$	38,568,360		$	(5,518	)	$	(19,122,924	)	$	19,448,822		$	155,502		$	19,604,324
Foreign Currency Translation											4,042						4,042			1,011			5,053
Non-controlling interest																				3,908			3,908
Net Gain/(Loss) for the period														249,244			249,244						249,244
Balance as of December 31, 2012		89,036,000		$	8,904		$	38,568,360		$	(1,476	)	$	(18,873,680	)	$	19,702,108		$	160,421		$	19,862,529

For the three months ended December 31, 2025

										Accumulated
					Additional					other		Total
	Common Stock				paid-in		Accumulated			comprehensive		stockholders’
	Shares		Amount		capital		deficit			income (loss)		deficit
Balance at October 1, 2025		114,785,005	$	11,479	$	31,594,254	$	(31,929,644	)	$	0	$	(323,911	)
Net loss for the period		-		-		-		(138,727	)		-		(138,727	)
Foreign currency translation adjustment		-		-		-		-			39		39
Balance at December 31, 2025		114,785,005	$	11,479	$	31,594,254	$	(32,068,371	)	$	39	$	(462,599	)

~~ALPHARx~~For the three months ended December 31, ~~INC.~~2024

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

										Accumulated
					Additional					other		Total
	Common Stock				paid-in		Accumulated			comprehensive		stockholders’
	Shares		Amount		capital		deficit			income (loss)		deficit
Balance at October 1, 2024		111,785,005	$	11,179	$	31,294,554	$	(31,671,468	)	$	0	$	(365,735	)
Net loss for the period		-		-		-		(14,710	)		-		(14,710	)
Foreign currency translation adjustment		-		-		-		-			-		-
Balance at December 31, 2024		111,785,005	$	11,179	$	31,294,554	$	(31,686,178	)	$	0	$	(380,445	)

~~FOR~~The ~~THE~~accompanying ~~THREE~~notes ~~MONTHS~~are ~~ENDED~~an ~~DECEMBER~~integral ~~31,~~part ~~2012~~of ~~AND~~these ~~2011~~consolidated financial statements.

~~(UNAUDITED)~~5 Table of Contents

	3 months ended December 31, 2012			3 months ended December 31, 2011
	(Unaudited)			(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Net Gain/(Loss)	$	253,152		$	(79,166	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		0			654
Changes in assets and liabilities:
Prepaid		(4,262	)		1,257
Deferred Financing Cost		0			0
Decrease/(Increase) in Accounts Receivable		(150,474	)		34,570
Decrease/(Increase) in Loan Receivable		(12,821	)
(Decrease) Increase in Accounts Payable and Accrued Liabilities		22,215			1,101
(Decrease) Increase in Accrued Interest on Notes Payable		4,470			46,220
Machinery & Equipment written off		0			3,402
Non-Controlling Interest		1,145			(1,285	)
NET CASH USED IN OPERATING ACTIVITIES		113,425			6,753
CASH FLOWS FROM INVESTING ACTIVITIES
Sold of Machinery and Equipment		0			0
NET CASH USED IN INVESTING ACTIVITIES		0			0
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance (repayment) of Notes Payable, net		(67,395	)		(26,842	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		(67,395	)		(26,842	)
Effect of exchange rate changes on cash and cash equivalents		5,369			3,893
NET INCREASE (DECREASE) IN CASH		51,399			(16,196	)
CASH and cash equivalents, beginning of year		4,342			30,386
CASH and cash equivalents, end of year	$	55,741		$	14,190
SUPPLEMENTARY DISCLOSURE:
Income Tax Paid	$	-		$	-
Interest Paid	$	11,683		$	-

UMEWORLD INC

~~(All~~CONDENSED ~~amounts~~CONSOLIDATED inSTATEMENTS USOF ~~Dollars)~~CASH FLOWS

6(UNAUDITED)

~~ALPHARX~~(Currency ~~INC.~~expressed in United States Dollars (“US$”), except for number of shares)

CONDENSED NOTES TO UNADUDTED INTERIM

	For the three months ended December 31,
	2025			2024

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(138,727	)	$	(14,710	)
Changes in assets and liabilities:
Accounts receivable		940			8
Deposit		(2,480	)
Prepayment		(1,248	)		(22,613	)
Inventory		(1,669,099	)		152
Accounts payable		1,667,848			14,788
Accrued liabilities and other payables		(1,216	)		(30,879	)
Due to related parties		50,494			-
NET CASH USED IN OPERATING ACTIVITIES		(93,488	)		(53,254	)

CASH FLOWS FROM FINANCING ACTIVITIES
Repayments to related parties		-			(6,280	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		-			(6,280	)
Effect of foreign exchange on cash		39
NET DECREASE IN CASH		(93,449	)		(59,534	)
Cash and cash equivalents at beginning of year		154,353			121,809
Cash and cash equivalents at end of year	$	60,904		$	62,275

~~CONSOLIDATED~~The ~~FINANCIAL~~accompanying ~~STATEMENTS~~notes are an integral part of these consolidated financial statements.

~~December~~6 ~~31,~~Table ~~2012~~of Contents

~~(UNAUDITED)~~UMEWORLD INC.

~~NOTE 1.~~ NOTES TO ~~INTERIM~~CONDENSED ~~UNAUDITED~~ CONSOLIDATED FINANCIAL STATEMENTS

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (~~consisting of all recurring accruals~~UNAUDITED) considered necessary for fair presentation have been included. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the year ended September 30, 2013. Interim unaudited consolidated financial statements should be read in conjunction with the Company’s annual audited financial statements for the year ended September 30, 2012 filed with SEC on Form 10K.

~~NOTE~~(Currency 2.expressed ~~NATURE~~in OFUnited ~~BUSINESS~~States ~~AND~~Dollars ~~GOING~~(“US$”), ~~CONCERN~~except for number of shares)

~~ALPHARx,~~NOTE ~~INC~~1. ~~(the~~NATURE ~~“Company”)~~OF ~~was~~BUSINESS ~~incorporated~~AND ~~under~~GOING ~~the~~CONCERN laws of the State of Delaware on August 7, 1997. The Company was engaged in the development of proven therapies by reformulating FDA approved and marketed drugs using its proprietary drug delivery technology. On November 4, 2011 the Company expanded its business operation to digital media with an intense focus on China.

~~The~~UMeWorld ~~interim~~Inc. ~~unaudited consolidated financial statements reflect~~ (the ~~activities~~“Company”) ofis ~~AlphaRx~~a ~~Inc.,~~holding ~~100%~~company offocused ~~AlphaRx~~on ~~Canada~~functional ~~Limited~~nutrition and ~~80%~~lipid-based ofconsumer ~~AlphaRx~~products ~~International Holdings Limited~~ and ~~AlphaRx~~conducts ~~Life~~its ~~Sciences~~operations ~~Ltd.~~through ~~(AIH’s~~ wholly owned ~~subsidiary)~~subsidiaries ~~collectively~~in the ~~“Company”. All~~United ~~material~~States ~~inter-company accounts~~ and ~~transactions have been eliminated~~Asia-Pacific.

The ~~accompanying~~Company’s ~~interim~~primary ~~unaudited~~operating ~~consolidated financial statements have been prepared on a going concern basis~~subsidiary, ~~which~~Dagola ~~contemplates the realization of assets and the satisfaction of liabilities in the normal course of business~~Inc. ~~Accordingly~~, ~~they~~conducts ~~do not include any adjustments relating to~~ the ~~realization~~sales, ofdistribution, ~~the carrying value of assets or the amounts~~ and ~~classification~~marketing of ~~liabilities~~DAGola® ~~that~~branded ~~might~~diacylglycerol be(“DAG”)-based ~~necessary~~cooking ~~should~~oil ~~the~~products ~~Company~~in ~~be unable to continue as a going concern. Continuance of~~ the ~~Company~~United asStates athrough ~~going~~online ~~concern~~marketplace ~~is dependent on its future profitability~~ and ~~on the on~~direct-~~going support of its shareholders, affiliates and creditors. Factors relating~~ to-consumer ~~going concern issues include working capital deficiencies, operating losses, shareholders’ deficits, and continued reliance on external funding sources~~channels. In order to mitigate the going concern issues, the Company is constantly pursuing new business arrangements and striving to achieve profitability, and seeking capital funding on an ongoing basis via the issuance of promissory notes, and private placements.

~~NOTE~~During 32025, the Company established an Asia-Pacific holding structure through Dagola Hong Kong Limited and its wholly owned PRC subsidiary, Guangzhou Duokanglong Special Medical Nutrition Technology Co., ~~NOTES~~Ltd. ~~PAYABLE~~In October 2025, ownership of Dagola Hong Kong Limited and its PRC subsidiary was transferred to the Company in a related-party transaction, after which both entities became wholly owned subsidiaries. The PRC subsidiary commenced revenue-generating sales activities in December 2025.

~~The~~On ~~Company~~October ~~repaid~~2, ~~$38~~2025,~~317~~ ~~in promissory notes during~~ the ~~three~~Company ~~months~~completed ~~ended~~its ~~December~~redomiciliation ~~31,~~from ~~2012.~~the ~~These~~British ~~notes~~Virgin ~~bear~~Islands ~~interest~~to atDelaware ~~12% per annum~~ and ~~are~~transitioned ~~repayable~~from ona ~~the~~foreign ~~first~~private ~~anniversary~~issuer ~~date~~to ofa ~~issuance~~U. ~~Previously issued promissory notes bear interest at rates of 8% - 12% per annum~~S. ~~Prepayment~~domestic ofissuer ~~these~~for ~~notes~~SEC ~~prior~~reporting ~~to the first anniversary date is permitted~~purposes.

~~See~~The ~~also~~Company ~~note~~consolidates 8all –entities ~~Related~~in ~~Party~~which ~~Transactions~~it holds a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. The Company does not utilize a variable interest entity structure.

7As of December 31, 2025, the Company’s consolidated subsidiary is as follows:

NOTE 4. NON-CONTROLLING INTEREST

Name	Date of Incorporation	Place of Incorporation	Percentage of Interest	Principal Activities	Nature of Company
Dagola Inc.	January 28, 2022	United States (Wyoming)	100%	Cooking oil sales and distribution	Operating subsidiary
Dagola Hong Kong Limited	August 25, 2025	Hong Kong	100%	Non-operating holding company	Holding subsidiary (inactive)
Guangzhou Duokanglong Special Medical Nutrition Technology Co., Ltd.	September 25, 2025	People’s Republic of China	100%	Cooking oil sales and distribution	Operating subsidiary

~~Effective~~Going June 22, 2006, AlphaRx International Holdings Ltd. (“AIH”) issued 1,500 shares of its common stock to New Super Limited (“NSL”) at a price of approximately $HK 6,667 per share or $HK 10 million in cash (USD $1,288,826). There were 10,000 common shares outstanding of which 8,500 or 85% belong to the Company. With the consolidation of only 85% of AIH, a non-controlling interest was established, representing net amounts owing to the non-controlling shareholder. The capital infusion into AIH is accounted for as additional paid in capital on the interim consolidated financial statements of the Company.Concern

OnThe ~~May~~accompanying ~~18,~~consolidated ~~2010,~~financial ~~AlphaRx~~statements ~~International~~have ~~Holdings~~been ~~Ltd.~~prepared ~~(“AIH”)~~assuming ~~issued~~that ~~625~~the ~~shares~~Company ofwill ~~its~~continue ~~common~~as ~~stock to New Super Limited (“NSL”) at~~ a ~~price~~going ofconcern ~~approximately~~and ~~$HK~~realize ~~2,166~~its ~~per~~assets ~~share, or $HK1,353,750 in cash (USD$173,292), representing a further 5% non-controlling interest~~ and ~~increasing~~satisfy ~~the~~its ~~total~~liabilities ofin the ~~non-controlling~~normal ~~interest~~course toof ~~20% after the infusion~~business.

~~NOTE~~For 5the quarter ended December 31, 2025, the Company incurred a net loss of $138,727. ~~COMMON~~As ~~STOCK~~of December 31, 2025, the Company had an accumulated deficit of $32,068,371 and a working capital deficiency of $462,599. These conditions, together with recurring operating losses and reliance on external financing, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are available to be issued.

~~The~~7 ~~Company~~Table ~~is authorized to issue 250,000,000 shares~~ of ~~common stock. As of December 31, 2012 there were 89,036,000 shares of Common Stock issued and outstanding with a stated par value of $0.0001 per share.~~Contents

~~NOTE~~Management’s 6.plans ~~STOCK~~to ~~OPTION~~alleviate ~~PLANS~~this substantial doubt include:

No· ~~options~~pursuing ~~were~~additional ~~granted~~business ~~nor~~arrangements ~~were~~and ~~any~~growth ~~exercised~~opportunities ~~during~~in the 3functional ~~months~~nutrition ~~ended~~and ~~December~~health-and-wellness ~~31,~~markets ~~2012.~~through ~~There~~Dagola; ~~remains~~· 0expanding ~~options~~distribution channels and product offerings to ~~purchase~~increase ~~shares~~revenues; ofand ~~Common~~· ~~Stock~~seeking asadditional ofcapital ~~December~~through 31promissory notes, ~~2012~~private placements, and other financing transactions.

~~During~~There ~~fiscal~~can ~~2009~~be ~~employees,~~no ~~officers~~assurance ~~and~~that ~~consultants~~these ~~exercised~~plans awill ~~total~~be ofsuccessful ~~3,430,000~~or ~~options~~that atadditional anfinancing ~~average~~will ~~exercise~~be ~~price~~available ofon ~~approximately~~acceptable ~~$0.08 per share and resulting in $274~~terms,~~750~~ inor ~~cash~~at ~~proceeds to the Company~~all. OfThe ~~these~~consolidated ~~options~~financial ~~700,000~~statements ~~were~~do ~~from~~not ~~the~~include ~~2000~~any ~~Plan~~adjustments ~~and~~that ~~had~~might aresult ~~weighted remaining contractual life of 2.5 years when exercised and 2,730,000 were~~ from the ~~2004~~outcome ~~Plan and had a weighted remaining contractual life~~ of ~~7.8~~this ~~years when exercised~~uncertainty. Immediately thereafter the remaining options in the 2000 Plan and 2003 Plan were cancelled, with the agreement of the option holders. In addition, and pursuant to an application for listing on the Toronto Venture Exchange, the Company cancelled a total of 7,660,000 options with the agreement of the option holders during fiscal 2008.

~~Proceeds~~NOTE ~~received by the Company from exercises of stock options are credited to Common Stock and additional paid-in capital~~2. SUMMARY ~~Additional~~OF ~~information~~SIGNIFICANT ~~with~~ACCOUNTING respect to the plan’s stock option activity is seen in the table below. The weighted average exercise price and remaining contractual life for all options seen at the bottom of the table was calculated by multiplying the number of options by the exercise prices or remaining lives and dividing the result by the total number of options. During fiscal 2008, with the agreement of the option holders, the option expiry date for all remaining 2004 Plan options was accelerated to June 30, 2012. All options now expire on or before June 30, 2012. The table below reflects remaining contractual life of the options as of December 31, 2012.POLICIES

AtBasis ~~the Company’s Annual General Meeting held November 26, 2008 a majority~~ of stockholders approved amendments to the existing Stock Incentive Plans including, among others: (i) combining the 2004 and 2006 Plans into one “2008 Stock Incentive Plan” for ease of administration; (ii) providing a cap for the number of options to be issued at 22,000,000; (iii) providing guidelines for exercise prices such that the exercise price of any newly granted option is never less than the market value or in the case of a 10%+ holder, never less than 110% of the market value on the date of grant; (iv) providing for a maximum term of 5 years for any option granted; (v) provide for a vesting schedule whereby vesting must occur over at least 18 months with no more than 1/6th of the options granted vesting in any 3 month period; (vi) providing for the maximum number of options to be granted to any one individual in any 12 month period to be no more than 5% of the issued and outstanding common stock, and (vii) providing for a maximum number of options to be granted to any Investor Relations party to be no more than 2% of the issued and outstanding common stock.presentation

8The accompanying interim unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

AsThe ainterim ~~result~~unaudited condensed consolidated balance sheet as of December 31, 2025 and the ~~new~~related ~~terms~~interim ~~governing~~unaudited condensed consolidated statements of operations and cash flows for the ~~Company’s~~three ~~Stock~~months ~~Incentive~~ended ~~Plan~~December 31, 2025 and 2024 have been prepared pursuant to the ~~maximum~~rules ~~number~~and regulations of ~~options~~the ~~that~~Securities ~~can~~and ~~still~~Exchange beCommission ~~issued~~(“SEC”) ~~totals~~and 4Regulation S-X. Accordingly,~~310,000~~ ~~regardless~~certain ofinformation ~~how~~and ~~many~~footnote ~~are~~disclosures ~~exercised~~normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or ~~expire~~omitted pursuant to such rules and regulations.

~~During~~These interim unaudited condensed consolidated financial statements and related notes should be read in conjunction with the ~~three~~Company’s ~~months~~audited consolidated financial statements and related notes for the fiscal year ended ~~December~~September 3130, ~~2012,~~2025 noincluded ~~options~~in ~~were~~the ~~granted~~Company’s ~~and~~Annual noReport ~~options~~on ~~were~~Form ~~exercised~~20-F, filed with the SEC on December 23, 2025. ~~Additional~~The ~~details~~Company ofcompleted its redomiciliation from the ~~2008~~British ~~Plan,~~Virgin asIslands atto ~~December~~Delaware 31on October 2, ~~2012~~2025 ~~are~~and asis ~~follows:~~now a U.S. domestic issuer

2008 Stock Option Plan	Number Granted, Exercised, Expired or Cancelled	Issue Date	Exercise Price $	Share Price on Grant Date $	Expiry Date	Remaining Contractual Life (Years)
Inception	0
Granted	12,720,000	15/11/2004	0.15	0.11	6/30/2012		0.5
Granted	500,000	15/11/2004	0.40 – 0.50	0.11	6/30/2012		0.5
Granted	7,000,000	10/1/2005	0.16	0.14	6/30/2012		0.5
Granted	390,000	8/2/2005	0.15	0.14	6/30/2012		0.5
Granted	100,000	5/25/2005	0.13	0.13	6/30/2012		0.5
Granted	3,290,000	10/17/2005	0.075	0.08	6/30/2012		0.5
Total	24,000,000
Exercised	(2,730,000)	12/27/2007	0.075	-	-		-
Cancelled	(6,640,000)	12/28/2007	-	-	-		-
Expired	(460,000)	2/10/2008	-	-	-		-
Remaining	14,170,000	-	-	-	-		-
Granted	90,000	1/3/2007	0.10	0.10	1/3/2012		0.008
Cancelled	(6,320,000)	9/30/2011	-	-	-		-
Expired	90,000	1/3/2007
Expired	700,000	11/15/2004
Expired	7,000,000	1/10/2005
Expired	50,000	2/8/2005
Expired	100,000	5/25/2005
Total	0	As at December 31, 2012
Weighted Average Exercise Price and Contractual Life of Options Remaining in Years			$0				0.00

In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position as of December 31, 2025 and the results of operations and cash flows for the interim periods presented have been included. Interim results are not necessarily indicative of results for the full fiscal year or any future period. Operating results for the three-month period ended December 31, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2026 or any future period.

9Principles of consolidation

~~NOTE~~The 7accompanying unaudited condensed consolidated financial statements include the accounts of UMeWorld Inc. ~~WARRANTS~~and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company consolidates all entities in which it holds a controlling financial interest, typically through ownership of a majority voting interest. Subsidiaries are included in the consolidated financial statements from the date control is obtained through the date control ceases.

OnDuring ~~January~~October 92025, ~~2012,~~ownership ~~the~~of ~~Company~~Dagola ~~issued~~Hong ~~150,000~~Kong ~~warrants~~Limited toand ~~purchase~~its ~~150~~wholly owned subsidiary,~~000~~ ~~shares~~Guangzhou ofDuokanglong ~~Common~~Special ~~Stock~~Medical atNutrition $0Technology Co.~~075~~, ~~per~~Ltd., ~~share~~was ~~expiring~~transferred onto ~~June~~the ~~30,~~Company ~~2014~~in a related-party transaction. OnFrom ~~September~~that ~~13,~~date ~~2011~~forward, both entities have been included in the Company’s ~~issued~~consolidated ~~250,000~~financial ~~warrants~~statements. toThe ~~purchase~~Company ~~250,000~~does ~~shares~~not ofconsolidate ~~Common~~any ~~Stock~~entities atunder ~~$0.075~~the ~~per~~variable ~~share~~interest ~~expiring~~entity onmodel ~~June~~and ~~30,~~does ~~2014~~not utilize a variable interest entity structure.

OnUse ~~April 12, 2010, the Company issued 3,740,150 warrants to purchase 3,740,150 shares~~ of Common Stock at $0.085 per share expiring on April 11, 2015. The warrants were issued in exchange for financial advisory services to be provided from the period from April 11, 2010 until Sep 30, 2010. The total fair value of the warrants has been estimated to be $262,090 using Black-Scholes option pricing model based on the following assumptions: dividend yield of 0%, expected volatility of 103.86%, risk-free interest rate of 3%, and an expected life of 5 years. The company recorded $262,090 in stock based compensation for the year ended September 30, 2010 (2009- $73,725). No income tax benefit has been realized as a result of warrant amortization expenses during 2010 and 2009. Stock based compensation is included in general and administrative expenses seen on the consolidated statement of operations and comprehensive loss.estimates

AsThe atpreparation ~~December~~of ~~31,~~the ~~2012~~unaudited ~~there~~condensed ~~were~~consolidated ~~1,508,030~~financial ~~(were~~statements ~~7,540,150~~in ~~before~~conformity 1with ~~for~~U.S. 5GAAP ~~reverse~~requires ~~split)~~management ~~warrants~~to ~~issued~~make estimates and ~~outstanding.~~assumptions ~~Additional~~that ~~details~~affect ~~regarding~~the ~~warrant~~reported ~~activity~~amounts of assets and ~~warrants~~liabilities ~~outstanding~~and the disclosure of contingent assets and liabilities as of ~~December~~the 31balance sheet date, ~~2012~~and ~~are~~the ~~seen~~reported inamounts of revenues and expenses during the ~~table~~periods ~~below~~presented.

Outstanding as at December 31, 2012	Issue Date	Exercise Price $	Share Price on Grant Date $	Expiry Date	Remaining Contractual Life (Years)	Reason for Issuance
3,000,000	4/1/2009	0.03	0.03	3/31/2014	1.25	Issued in exchange for financial advisory services.
3,740,150	4/12/2010	0.085	0.085	4/11/2015	2.28	Issued in exchange for financial advisory services.
400,000	8/3/2011	0.075	0.04	6/30/2014	1.50	Issued in exchange for Private Placement.
250,000	9/13/2011	0.075	0.05	6/30/2014	1.50	Issued in exchange for Private Placement
150,000	1/9/2012	0.075	0.05	6/30/2014	1.50	Issued in exchange for Private Placement
Total		Weighted Average Exercise Price			Weighted Average Contractual Life (Years)
7,540,150		$ 0.06			1.787

Significant estimates reflected in the Company’s unaudited condensed consolidated financial statements include, but are not limited to, inventory valuation and obsolescence reserves, impairment of long-lived assets, realizability of deferred tax assets, and other valuation allowances, where applicable. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

~~NOTE~~ 8. ~~RELATED~~Table ~~PARTY~~of ~~TRANSACTIONS~~Contents

~~The~~Cash ~~Company sources some of its funding in the form of promissory notes from Michael Lee – President~~ and ~~CEO.~~cash The Company is indebted to Mr. Lee in the amount of $76,820 including accrued interest of $26,061 as of December 31, 2012. The directors did not loan any funds to the Company during the three months ended December 31, 2012. These promissory notes bear interest at 12% per annum and are unsecured.equivalents

10Cash and cash equivalents consist of cash on hand, demand deposits with financial institutions, and highly liquid investments with original maturities of three months or less at the time of purchase.

~~NOTE~~Revenue ~~9. RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS~~Recognition

InThe ~~December~~Company ~~2007,~~recognizes ~~the~~revenue ~~FASB~~in ~~updated~~accordance ~~FASB~~with ASC ~~Subtopic~~Topic ~~810-10~~606, ~~Consolidation~~Revenue ~~(formerly~~from ~~SFAS~~Contracts ~~No.~~with ~~160)~~Customers. ~~This~~Revenue ~~guidance~~is ~~establishes~~recognized ~~accounting~~when ~~and~~control ~~reporting~~of ~~standards~~goods ~~for~~is ~~non-controlling~~transferred ~~interests~~to incustomers ~~subsidiaries. The guidance clarifies that a non-controlling interest~~ in aan ~~subsidiary be accounted for as a component of equity, but separate from the parent’s equity. Furthermore, the~~ amount ofthat ~~consolidated~~reflects ~~net income attributable to~~ the ~~parent~~consideration ~~and~~ the ~~non-controlling interest must be clearly identified and presented on the face of the Consolidated Statements of Operations. The~~ Company ~~adopted~~expects ~~the~~to ~~provisions~~receive ofin ~~the~~exchange ~~guidance effective October 1, 2009 and the provisions are being applied prospectively, except~~ for ~~the~~those ~~presentation and disclosure requirements, which have been applied retrospectively~~goods. ~~The adoption did not have a material impact on our consolidated financial statements.~~

~~Recent~~The ~~Issued~~Company’s ~~Standards~~revenue consists primarily of sales of DAG-based cooking oil and related health and wellness products through online marketplace platforms and distributor channels in the United States and Asia-Pacific. Revenue is recognized at a point in time when control of the product transfers to the customer, which is generally upon shipment or delivery, depending on contractual terms and the nature of the sales channel.

InThe ~~April~~Company ~~2011,~~applies the ~~FASB~~five-step ~~issued~~model ~~ASU~~under ~~2011-03,~~ASC ~~Consideration~~606 ofto ~~Effective~~its ~~Control~~customer oncontracts: ~~Repurchase~~(i) ~~Agreements,~~identify ~~which~~the ~~deals~~contract with the ~~accounting~~customer, ~~for~~(ii) ~~repurchase~~identify ~~agreements and other agreements that both entitle and obligate a transferor to repurchase or redeem financial assets before their maturity. ASU 2011-03 changes~~ the ~~rules~~performance ~~for determining when these transactions should be accounted for as financings~~obligations, as(iii) ~~opposed~~determine ~~to sales. The guidance in ASU 2011-03 is effective for~~ the ~~first~~transaction ~~interim or annual period beginning on or after December 15~~price, ~~2011.~~(iv) ~~The~~allocate ~~guidance~~the ~~should~~transaction beprice ~~applied prospectively~~ to ~~transactions~~the orperformance ~~modifications~~obligations, ofand ~~existing~~(v) ~~transactions~~recognize ~~that~~revenue ~~occur~~when ~~on or after~~ the ~~effective~~performance ~~date.~~obligation ~~Early adoption~~ is ~~not permitted~~satisfied. ~~The~~For ~~adoption~~product ofsales, ~~ASU 2011-03 is not expected to have a material impact on~~ the Company’s ~~financial~~contracts ~~condition~~generally orcontain ~~results~~a ofsingle ~~operation~~performance obligation.

InThe ~~May~~transaction ~~2011,~~price ~~the~~is ~~FASB~~based ~~issued~~on ~~ASU~~the ~~2011-04~~invoiced amount, ~~Fair~~net ~~Value~~of ~~Measurement~~estimated ~~(Topic~~variable ~~820):~~consideration, ~~Amendments~~including toexpected ~~Achieve~~returns, ~~Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (“IFRS”). ASU 2011-04 clarifies some existing concepts~~discounts, ~~eliminates wording differences between U.S. GAAP and IFRS~~promotions, and inplatform ~~some limited cases~~fees, ~~changes~~where ~~some principles to achieve convergence between U~~applicable.S. ~~GAAP~~Estimates ~~and~~of ~~IFRS.~~variable ~~ASU~~consideration ~~2011-04~~are ~~results~~included in arevenue ~~consistent~~only ~~definition~~to ~~of fair value and common requirements for measurement of and disclosure about fair value between U.S. GAAP and IFRS. ASU 2011-04 also expands~~ the ~~disclosures~~extent ~~for~~that ~~fair~~it ~~value~~is ~~measurements~~probable that ~~are~~a ~~estimated using~~ significant ~~unobservable~~reversal ~~(Level 3) inputs. ASU 2011-04~~ will ~~be effective for the Company beginning after December 15, 2011. The Company does~~ not ~~expect the adoption of ASU 2011-04 to have a material effect on its operating results or financial position~~occur.

InPayments ~~June~~received ~~2011,~~in ~~the~~advance ~~Financial Accounting Standard Board (“FASB”) issued Accounting Standard Update (“ASU”) 2011-05, Presentation~~ of ~~Comprehensive~~shipment ~~Income,~~are ~~which~~recorded ~~requires~~as ancontract ~~entity~~liabilities toand ~~present~~recognized ~~the~~as ~~total~~revenue ofwhen ~~comprehensive~~control ~~income, the components~~ of ~~net income, and~~ the ~~components~~goods ofis ~~other comprehensive income either in a single continuous statement of comprehensive income, or in two separate but consecutive statements~~transferred. ~~ASU~~Shipping ~~2011-05~~and ~~eliminates~~handling ~~the~~amounts ~~option~~charged to ~~present~~customers ~~components~~are ofincluded ~~other~~in ~~comprehensive income as part of the statement of equity. ASU 2011-05 will be effective for the Company beginning after December 15~~revenue, ~~2011.~~and ~~The Company does not expect~~ the ~~adoption~~related ofcosts ~~ASU~~are ~~2011-05~~included toin ~~have~~cost ~~a material effect on its operating results or financial position. However, it will impact the presentation~~ of ~~comprehensive income~~revenue.

InAccounts September 2011, the FASB has issued Accounting Standards Update (ASU) No. 2011-08, Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment. ASU 2011-08 is intended to simplify how entities, both public and nonpublic, test goodwill for impairment. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is "more likely than not" that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in Topic 350, Intangibles-Goodwill and Other. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted, including for annual and interim goodwill impairment tests performed as of a date before September 15, 2011, if an entity’s financial statements for the most recent annual or interim period have not yet been issued or, for nonpublic entities, have not yet been made available for issuance.Receivable

11Accounts receivable are recorded at invoiced amounts and are non-interest bearing. The Company evaluates receivables for expected credit losses and records an allowance when collection is not considered probable based on historical experience, customer creditworthiness, and current economic conditions. As of December 31, 2025 and September 30, 2025, there was no allowance for expected credit losses.

In July 2012, the FASB has issued Accounting Standards Update (ASU) No. 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. This ASU states that an entity has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Codification Subtopic 350-30, Intangibles—Goodwill and Other, General Intangibles Other than Goodwill.Inventory

~~Under~~Inventory ~~the~~consists ~~guidance~~of infinished ~~this~~goods ~~ASU, an entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period~~ and ~~proceed~~is ~~directly~~stated toat ~~performing~~ the ~~quantitative~~lower impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The amendments in this ASU are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted, including for annual and interim impairment tests performed as of acost ~~date~~or ~~before~~net ~~July~~realizable 27value, ~~2012,~~with ifcost adetermined ~~public~~using ~~entity’s financial statements for~~ the ~~most recent annual or interim period have not yet been issued or~~first-in, ~~for~~first-out ~~nonpublic~~(FIFO) ~~entities, have not yet been made available for issuance~~method.

InThe ~~August~~Company ~~2012,~~records ~~the~~write-downs ~~FASB~~for ~~has~~excess, ~~released Accounting Standards Update (ASU) No. 2012~~slow-03moving, ~~Technical~~or ~~Amendments~~obsolete ~~and~~inventory ~~Corrections~~based toon ~~SEC~~forecasted ~~Sections: Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 114~~demand, ~~Technical~~product ~~Amendments~~shelf ~~Pursuant to SEC Release No. 33-9250~~life, and ~~Corrections~~market ~~Related~~conditions. toSuch ~~FASB Accounting Standards Update 2010~~write-~~22.~~downs ~~This~~are ~~ASU~~included ~~amends~~in ~~various~~cost ~~SEC paragraphs: (a) pursuant to the issuance~~ of ~~Staff~~revenue. ~~Accounting Bulletin~~ No. ~~114;~~inventory ~~(b)~~write-offs ~~pursuant~~were torecorded during the ~~issuance~~three ofmonths ~~the~~ended ~~SEC’s~~December ~~Final Rule~~31, ~~Technical~~2025. ~~Amendments~~For ~~to Commission Rules and Forms Related to~~ the ~~FASB’s~~year ~~Accounting~~ended ~~Standards~~September ~~Codification~~30, ~~Release~~2025, ~~Nos.~~the ~~33-9250,~~Company ~~34-65052,~~recorded ~~and~~inventory ICwrite-~~29748~~offs ~~August~~totaling 8$29, ~~2011; and (c) related to ASU No~~493. ~~2010-22, Accounting for Various Topics.~~

~~NOTE~~Cost ~~10.~~of ~~TRANSACTION ADJUSTMENTS~~Revenue

~~Additional~~Cost ~~accumulated differences derived from the beginning balances~~ of ~~Non-controlling~~revenue ~~Interest~~consists ~~and~~primarily ~~Additional-paid-in capital carryover from previous periods is adjusted to reflect the correct balancing figures. This adjustment is a change~~ of ~~accounting~~product ~~estimation~~acquisition oncosts, ~~applicable~~contract ~~foreign~~manufacturing ~~exchange rate on various transactions~~ and ~~its~~bottling ~~carryover~~costs, ~~effects.~~packaging ~~This~~materials, ~~change~~freight ofand ~~estimation~~import ischarges, ~~not~~fulfillment ~~material~~fees, and ~~has~~platform nodistribution ~~impact~~costs onassociated ~~current~~with ~~period~~product ~~statement of income or operation results~~sales.

12Foreign Currency Translation

~~NOTE~~The 11Company’s reporting currency is the U.S. ~~RECLASSIFICATIONS~~dollar. For the three months ended December 31, 2025 and 2024, revenues and expenses denominated in foreign currencies were translated into U.S. dollars using average exchange rates of approximately RMB 7.09 and RMB 7.19 per U.S. dollar, respectively. Assets and liabilities denominated in foreign currencies were translated using the exchange rates in effect at December 31, 2025 and September 30, 2025, respectively. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss).

~~Certain~~9 ~~amounts~~Table ~~from~~of ~~prior year have been reclassified to conform to current year’s presentation.~~Contents

~~NOTE~~Related ~~12.~~Party ~~SUBSEQUENT EVENTS~~Transactions

The Company ~~has~~follows ~~evaluated~~ASC ~~all~~Topic ~~other~~850, ~~subsequent~~Related ~~events through February 22~~Party, ~~2013,~~for the ~~date~~identification ~~these~~of ~~consolidated~~related ~~financial~~parties ~~statements were issued~~ and ~~determined that there were no other subsequent events or transactions that require recognition or disclosures in~~ the ~~financial~~disclosure ~~statements except the acquisition~~ of ~~UMeLook~~related onparty ~~August~~transactions. ~~30,~~Transactions ~~2012~~with ~~which~~related ~~will~~parties ~~contain~~are arecorded ~~British~~at ~~Virgin~~amounts ~~Islands~~agreed ~~holding~~upon ~~company,~~between athe ~~Hong~~parties. ~~Kong~~Related ~~intermediate-holding~~party ~~company,~~balances ~~a People’s Republic of China (“PRC”) wholly foreign owned enterprise (“WFOE”) subsidiary~~ and atransactions ~~PRC~~are ~~operation~~disclosed ~~company~~separately ~~which will hold the web license while under the financial control of the WFOE~~ in ~~a Variable Interest Entity (“VIE”) structure. This set-up is not yet completed. Therefore, part of~~ the ~~acquisition~~accompanying ~~becomes~~notes ~~a deposit which is pending on the completion of the corporate structure~~ to ~~determine~~ the ~~final~~unaudited ~~value~~condensed ~~allocation~~consolidated onfinancial ~~the consideration of the acquisition~~statements.

13Income Taxes

~~ITEM~~The 2Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ~~MANAGEMENT'S~~Current ~~DISCUSSION~~income ~~AND~~taxes ~~ANALYSIS~~are OFprovided ~~FINANCIAL~~based ~~CONDITION~~on ~~AND~~taxable ~~RESULTS~~income OFfor ~~OPERATION~~the period using enacted tax rates applicable in the jurisdictions in which the Company operates.

~~The~~Deferred ~~following~~tax ~~discussion~~assets ~~should~~and beliabilities ~~read~~are inrecognized ~~conjunction~~using ~~with~~ the ~~information~~asset ~~contained in the consolidated financial statements of the Company~~ and ~~the~~liability ~~notes~~method ~~thereto~~for ~~appearing~~temporary ~~elsewhere~~differences ~~herein~~between ~~and in conjunction with~~ the ~~Management's~~financial ~~Discussion~~statement ~~and~~carrying ~~Analysis~~amounts of ~~Financial~~assets ~~Condition~~ and ~~Results~~liabilities ofand ~~Operations~~their ~~set~~respective ~~forth~~tax inbases. ~~(1)~~Deferred ~~the~~tax ~~Company's~~assets ~~Annual~~and ~~Report~~liabilities onare ~~Form~~measured ~~10-K~~using ~~for~~enacted ~~the~~tax ~~year~~rates ~~ended~~expected ~~September~~to ~~30,~~apply ~~2012.~~in ~~Readers should carefully review~~ the ~~risk~~periods ~~factors disclosed~~ in ~~this~~which ~~Form~~the ~~10-K~~temporary ~~and~~differences ~~other~~are ~~documents~~expected ~~filed~~to bybe ~~the~~realized ~~Company~~or ~~with the SEC~~settled.

AsDeferred ~~used~~tax inassets ~~this~~are ~~report,~~recognized only to the ~~terms~~extent ~~"Company,"~~that ~~"AlphaRx"~~it ~~"we,"~~is ~~"us,"~~more ~~and~~likely ~~"our,"~~than ~~refer~~not ~~collectively~~that tothey ~~AlphaRx~~will ~~Inc~~be realized., ~~AlphaRx~~A ~~Canada~~valuation ~~Limited,~~allowance ~~our~~is ~~wholly~~recorded ~~owned~~when ~~subsidiary~~management ~~and~~determines ~~80%~~that it is more likely than not that some or all of ~~AlphaRx~~a ~~International~~deferred ~~Holdings~~tax ~~Limited~~asset will not be realized.

~~PRELIMINARY~~The ~~NOTE~~Company ~~REGARDING~~recognizes ~~FORWARD-LOOKING~~the ~~STATEMENTS~~benefit of an uncertain tax position only if it is more likely than not that the position will be sustained upon examination by the relevant taxing authority. The amount recognized is the largest amount of tax benefit that is greater than 50 percent likely to be realized upon settlement. Interest and penalties related to income taxes, if any, are recognized as a component of income tax expense. No material interest or penalties were recognized for the three months ended December 31, 2025 and 2024.

This Quarterly Report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "the Company believes," "management believes" and similar language. The ~~forward-looking statements are based on the current expectations of the~~ Company ~~and~~operates ~~are~~in ~~subject~~multiple totax ~~certain risks~~jurisdictions, ~~uncertainties and assumptions,~~ including ~~those~~the ~~set~~United ~~forth~~States inand the ~~discussion under "Management'~~People’s ~~Discussion~~Republic ~~and Analysis~~ of Financial Condition and Results of Operations" in this report. Actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to usChina, and weis ~~assume~~subject ~~no obligation~~ to ~~update~~examination ~~them.~~by ~~Investors~~taxing ~~are~~authorities ~~also advised to refer to the information~~ in ~~our~~those previous filings with the Securities and Exchange Commission (SEC), especially on Forms 10-K, 10-Q and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic resultsjurisdictions. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

~~General~~Comprehensive Income (Loss)

~~AlphaRx~~Comprehensive ~~Inc.,~~income ~~formerly~~(loss) ~~known~~consists asof ~~Logic~~two ~~Tech~~components: ~~International~~net ~~Inc.,~~income ~~was~~(loss) ~~incorporated in Delaware on August 8, 1997 as an intellectual property holding company whose mission was to identify, acquire~~ and ~~develop~~other ~~new~~comprehensive ~~technologies~~income ~~or products and devise commercial applications to be taken to market through licensing or joint venture partners~~(loss). ~~Logic~~Net ~~Tech~~income International Inc. was renamed AlphaRx Inc. on January 28, 2000 and our Common Stock commenced trading on the OTC Pink Sheets under the symbol "AHRX" on July 25, 2000. On October 12, 2000 AlphaRx Inc. Common Stock ceased trading on the Pink Sheets and began trading on the Over The Counter Bulletin Board (~~“OTCBB”~~loss) ~~under~~includes ~~the~~all ~~same symbol. Subsequent to March 19~~revenues, ~~2002 AlphaRx Inc.’s symbol was changed to “ALRX” after a consolidation of its Common Stock on a 1 new for 5 old basis. On April 20~~expenses, ~~2012~~gains, ~~the Company effected a consolidation of its share capital on the ratio of one new share for five old shares~~ and ~~began~~losses ~~trading~~recognized onin ~~a split-adjusted basis on May 29, 2012. On July 23, 2012 AlphaRx Inc. Common Stock ceased trading on~~ the ~~OTCBB~~condensed ~~and~~consolidated ~~began~~statements ~~trading on the OTCQB Marketplace under the same symbol “ALRX” on account~~ of ~~its ineligibility for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11~~operations. ~~All references to AlphaRx Inc. Common Stock have been retroactively restated.~~

14Other comprehensive income (loss) includes gains and losses that are recorded directly in stockholders’ equity and are excluded from net income under U.S. GAAP. For the Company, other comprehensive income (loss) consists primarily of foreign currency translation adjustments arising from the translation of the financial statements of subsidiaries whose functional currencies are not the U.S. dollar.

~~Recent~~Earnings ~~Developments~~(Loss) Per Share

AlphaRx is a specialty pharmaceutical company dedicated to developing therapies to treat and manage pain. Prior to November, 2011, the business of the Company was focused on reformulating FDA approved and marketed drugs using its proprietary site-specific nano drug delivery technology. From 2000 until June 2011, substantial efforts and resources were devoted to understanding our nano drug delivery technology and establishing a product development pipeline that incorporated this technology with selected molecules. On July, 2011 the Board and management adopted a new business plan that it believed would improve the Company’s performance. The ~~new business plan narrowed the~~ Company’s ~~focus~~computes toearnings developing and commercializing 2 existing product candidates Indaflex and ARX 8203 for the pain market. On November 4, 2011 the Company adopted a new corporate development strategy that expanded the business operation of the Company to digital media with an intense focus on China. On August 30, 2012, the Company acquired all of the issued and outstanding shares of UMeLook Holdings Limited (~~“UMeLook”~~loss), a digital media startup with an intense focus on China. The acquisition of UMeLook was completed as a share exchange through the issuance of 70,000,000 common shares of AlphaRx Inc. to the shareholders of UMeLook at a deemed price of $0.30 per share in ~~exchange~~accordance ~~for~~with ~~all~~ASC ofTopic ~~the~~260, ~~issued~~Earnings ~~and~~Per ~~outstanding shares in the capital of UMeLook~~Share. ~~There~~Basic ~~were~~earnings no change of control of our officers and Board of Directors as a result of the Transaction. The acquisition of UMeLook will contain a British Virgin Islands holding company, a Hong Kong intermediate-holding company, a People’s Republic of China (~~“PRC”~~loss) ~~wholly~~per ~~foreign~~share ~~owned~~is ~~enterprise~~calculated ~~(“WFOE”)~~by ~~subsidiary~~dividing ~~and~~net aincome ~~PRC operation company which will hold the web license while under the financial control of the WFOE in a Variable Interest Entity~~ (~~“VIE”~~loss) ~~structure.~~attributable ~~This~~to ~~set-up~~common isstockholders ~~not~~by ~~completed yet. Therefore, part of~~ the ~~acquisition~~weighted ~~becomes~~average anumber ~~deposit which is pending on the completion~~ of ~~the~~common ~~corporate~~shares ~~structure~~outstanding toduring ~~determine~~ the ~~final value allocation on the consideration of the acquisition~~period.

~~Overview~~Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as options, warrants, or convertible instruments, were exercised or converted into common shares. Diluted earnings (loss) per share is computed using the weighted average number of ~~Results~~common shares outstanding plus the effect of ~~Operations~~potentially dilutive common shares, when dilutive.

Three Months Ended	Dec 31 2012 $		Sep 30 2012 $			Jun 30 2012 $			Mar 31 2012 $		Dec 31 2011 $			Sep 30 2011 $			Jun 30 2011 $			Mar 31 2011 $
Net Sales		370,329		69,659			30,513			30,948		35,683			77,417			31,866			51,390
Net Income (Loss)		253,152		(69,409	)		(31,457	)		87,140		(79,166	)		(150,078	)		(106,655	)		(113,657	)
Net Income (Loss) per Share (1)		0.0029		(0.0016	)		(0.0016	)		0.0009		(0.001	)		(0.002	)		(0.001	)		(0.001	)

Potential common shares are excluded from the diluted earnings (loss) per share calculation when their effect would be anti-dilutive, including periods in which the Company reports a net loss.

~~NOTE~~For ~~(1)~~the ~~Net~~three ~~Loss~~months ~~per~~ended ~~share~~December on31, a2025 ~~quarterly~~and ~~basis~~2024, ~~does~~diluted ~~not~~loss ~~equal~~per ~~net~~share ~~Loss~~is the same as basic loss per share ~~for~~because the ~~annual~~inclusion ~~periods~~of ~~due~~potential tocommon ~~rounding~~shares would have been anti-dilutive.

1510 Table of Contents

~~RESULTS~~Segment ~~OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2012, AS COMPARED TO THE THREE MONTHS ENDED DECEMBER 31, 2011~~Reporting

The Company ~~incurred~~operates as a ~~net~~single ~~gain~~operating ofand ~~$253~~reportable segment,~~152~~ ~~for~~as the ~~three~~chief ~~month~~operating ~~period~~decision ~~ended~~maker ~~December~~reviews ~~31,~~financial ~~2012~~information ason ~~compared to~~ a ~~net~~consolidated ~~loss~~basis ~~of $79,166 incurred~~ for ~~the~~purposes ~~same period a year ago, an increase~~ of ~~$332,318. Revenues~~evaluating ~~during~~performance ~~the three months ended December 31, 2012 were about $334,646 more than in the previous period; general~~ and ~~administrative~~allocating ~~expenses were about $6,575 more than in previous period respectively~~resources.

~~Revenues~~Commitments and Contingencies

~~Total~~The ~~revenues~~Company accounts for ~~the~~contingencies ~~three-month~~in ~~period~~accordance ~~ended~~with ~~December~~ASC 31Topic 450-20, ~~2012~~Contingencies. ~~were~~Certain ~~$370,329~~conditions asmay ~~compared~~exist toas ~~$35,683~~of ~~generated~~the ~~for~~date the ~~same~~financial ~~period~~statements are issued that may result in a ~~year~~loss ~~ago,~~to anthe ~~increase~~Company ~~of $334,646~~but will be resolved only when one or ~~about~~more ~~937%~~future events occur or fail to occur. The ~~increase~~Company isassesses ~~due~~such contingent liabilities, and such assessment inherently involves the exercise of judgment. In assessing loss contingencies related to legal proceedings pending against the ~~outright~~Company ~~sale~~or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of ~~Indaflex~~such ~~Mexican~~proceedings ~~right~~or toclaims, ~~our~~as ~~licensee~~well ~~Andromaco~~as the perceived merits of the amount of relief sought or expected to be sought.

~~General~~If the assessment of a contingency indicates that it is probable that a material loss has been incurred and ~~Administrative~~the ~~Expenses~~amount of the liability can be reasonably estimated, the estimated liability is accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is reasonably possible, or is probable but cannot be reasonably estimated, the nature of the contingent liability and an estimate of the range of possible loss, if determinable and material, are disclosed.

~~General~~Loss ~~and~~contingencies ~~Administrative~~considered ~~expenses~~remote ~~consist~~are ~~primarily~~generally ofnot ~~personnel~~disclosed ~~costs~~unless ~~related~~they toinvolve ~~general management functions~~guarantees, ~~finance,~~in ~~office~~which ~~overheads,~~case asthe ~~well~~guarantees asare ~~insurance costs and professional fees related to legal, audit and tax matters~~disclosed.

~~General~~From ~~and~~time ~~Administrative~~to ~~expenses~~time, ~~were~~the ~~$96,757~~Company ~~for~~may be involved in legal proceedings and claims arising in the ~~three~~ordinary ~~month~~course ~~period~~of ~~ended~~business. As of December 31, ~~2012~~2025, asthe ~~compared~~Company is not a party to ~~$90~~any material legal proceedings,~~182~~ ~~incurred~~and ~~for~~management ~~the~~is ~~same~~not ~~period~~aware of any pending or threatened claims that are expected to have a ~~year~~material ~~ago~~adverse effect on the Company’s consolidated financial position, anresults ~~increase~~of operations, or cash flows. However, there can be no assurance that future developments will not materially adversely affect the Company’s business, financial position, results of $6operations,~~575~~ or ~~about~~cash 7flows.~~3%.~~

~~Research~~Fair ~~and~~Value ~~Development~~of ~~Expenses~~Financial Instruments

~~Research~~The ~~and~~Company ~~development~~accounts ~~expenses~~for ~~include~~fair ~~costs~~value ~~for~~measurements ~~scientific~~in ~~personnel~~accordance with ASC Topic 820, ~~supplies~~Fair Value Measurement, ~~equipment~~which defines fair value, ~~and~~establishes ~~outsourced~~a ~~clinical~~three-level hierarchy for inputs used in measuring fair value, and ~~other~~requires ~~research~~related ~~activities~~disclosures.

~~Research~~The ~~and~~fair ~~development~~value ~~expenses~~hierarchy ~~for~~prioritizes the ~~three~~inputs ~~months~~used ~~ended December 31, 2012 and December 31, 2011 were $0. The Company does not foresee any substantial R&D expenses~~ in ~~the~~valuation ~~near~~techniques ~~future.~~as follows:

~~Depreciation~~· Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2 — observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data. · Level 3 — unobservable inputs that are supported by little or no market activity and are significant to the fair value measurement.

~~Depreciation~~Financial ~~totalled~~assets $0and ~~for~~liabilities ~~the~~are ~~three~~classified ~~months ended December 31, 2012~~ as ~~compared~~Level to3 ~~$654~~when ~~incurred~~their ~~during~~fair ~~the~~values ~~same~~are ~~period~~determined ausing ~~year~~pricing ~~ago~~models, adiscounted ~~decrease~~cash offlow ~~$654~~methodologies, or ~~about~~similar ~~100%. Our~~valuation ~~capital~~techniques ~~asset purchases were minimized during the last fiscal year. Certain assets are now fully depreciated resulting~~ in ~~decreasing~~which ~~depreciation~~at ~~expense. Should~~least ~~any~~one ~~assets~~significant ~~become~~assumption ~~permanently~~or ~~impaired~~input ~~they~~is ~~are written off to income as determined~~unobservable.

~~Gain/(Loss)~~If ~~from~~the ~~Operations~~inputs used to measure the fair value of financial assets and liabilities fall within different levels of the hierarchy, the classification is based on the lowest level input that is significant to the fair value measurement.

~~Gain~~The ~~from~~carrying ~~operations~~amounts ~~were~~of ~~$273,572~~financial ~~for~~instruments ~~the~~included ~~three~~in ~~months~~current ~~ended~~assets ~~December~~and 31current liabilities, ~~2012~~including ascash, ~~compared~~accounts toreceivable, aaccounts ~~net~~payable, ~~loss~~and ofaccrued ~~$55~~liabilities,~~153~~ ~~incurred~~approximate ~~for~~fair ~~the~~value ~~same period a year ago. The gain is~~ due to ~~the~~their ~~outright~~short-term ~~sale of Indaflex Mexican right to our licensee Andromaco~~maturities.

1611 Table of Contents

~~Interest~~Recently ~~Expense~~Issued Accounting Pronouncements

~~Interest~~The ~~expense~~Company ~~for~~has ~~the~~reviewed ~~three~~accounting ~~months~~standards ~~ended~~issued ~~December~~by ~~31,~~the ~~2012~~Financial ~~was~~Accounting ~~$24,395~~Standards asBoard ~~compared~~(“FASB”) tothrough ~~interest~~the ~~expense~~date of ~~$24~~issuance of these condensed consolidated financial statements. The Company does not believe that any other recently issued,~~013~~ ~~generated~~but ~~during~~not ~~the~~yet ~~same~~effective, ~~period~~accounting pronouncements will have a ~~year~~material ~~ago~~impact on its condensed consolidated financial statements.

~~Non-Controlling~~NOTE ~~interest in gain/(loss) of Consolidated Subsidiaries~~3. INVENTORIES

WeInventories ~~reflected~~consist ~~a non-controlling interest income~~ of ~~$1,011 for~~ the three months ended December 31, 2012 as compared to a non-controlling interest loss of $522 for the same period a year ago. Non-Controlling interest represents our minority shareholder’s proportionate interest (which is 20%) in our 80% owned subsidiary – AIH. The non-controlling interest resulted in the investment in our subsidiary AlphaRx International Holdings Ltd. by an independent third party – New Super Ltd. during June 2006. On 5/18/2010, New Super Ltd. had infused an additional $173,237 in exchange of an additional 5% ownership of our subsidiary AlphaRx International Holdings Ltd.following:

Net Gain/(Loss)

	As of
	December 31, 2025		September 30, 2025
Finished goods	$	1,682,509	$	13,410
	$	1,682,509	$	13,410

As aof ~~result~~December of31, 2025, the ~~above~~increase ~~mentioned~~in ~~revenue~~finished ~~and~~goods ~~expense~~inventory ~~items,~~primarily werelates ~~incurred~~to ainitial ~~net~~product ~~gain~~stocking ofassociated ~~$253,152~~with ~~for~~ the ~~three~~start ~~months~~of ~~ended~~sales ~~December~~activity ~~31,~~in ~~2012~~the asAsia-Pacific ~~compared~~region tofollowing athe ~~net~~incorporation ~~loss~~ of ~~$79,166~~the ~~generated~~Company’s inHong ~~the~~Kong ~~same~~and ~~period~~PRC asubsidiaries. ~~year~~Inventory ~~ago.~~levels ~~The~~related ~~gain~~to isUnited ~~due~~States tooperations ~~the~~were ~~outright~~generally ~~sale~~consistent ofwith ~~Indaflex~~those ~~Mexican~~reported ~~right~~at tothe ~~our~~fiscal ~~licensee~~year ~~Andromaco~~end of September 30, 2025.

~~LIQUIDITY~~No ~~AND~~inventory ~~CAPITAL~~write-offs ~~RESOURCES~~were recorded during the three months ended December 31, 2025. For the year ended September 30, 2025, the Company recorded inventory write-offs totaling $29,493.

AsNOTE ~~at December 31, 2012 the Company had a working capital of $19,209,492 as compared to a working capital of $19,025,582 as at September 30, 2012~~4. ~~The~~ACCOUNTS ~~Company has also increased its stockholders’ gain to $19~~PAYABLE,~~862,529~~ asACCRUED atLIABILITIES ~~December~~AND ~~31,~~OTHER ~~2012 compared to a stockholders’ gain of $19,604,324 as at September 30, 2012. We did not issue any stock during the three months ended December 31, 2012.~~PAYABLES

~~Since~~Accounts ~~inception~~payable, weaccrued ~~have~~liabilities ~~financed~~and ~~operations~~other ~~primarily~~payables ~~from~~consist ~~the issuance~~ of ~~Common~~the ~~Stock. We expect to continue Common Stock issuances and issuance of promissory notes to fund our ongoing activities.~~following:

We currently do not have sufficient resources to complete the commercialization of our drug products or to carry out our entire business strategy. Therefore, we will need to raise additional capital to fund our operations sometime in the future. We cannot be certain that any financing will be available when needed. Any additional equity financings will be dilutive to our existing stockholders, and debt financing, if available, may involve restrictive covenants on our business and also the issuance of warrants or conversion features which may further dilute our existing stockholders.

	As of
	December 31, 2025		September 30, 2025
Accounts payable	$	1,670,243	$	2,395
Accrued liabilities and other payables	$	211,340	$	212,556
Total	$	1,881,583	$	214,951

WeAccounts ~~expect~~payable torepresents ~~continue~~amounts due to ~~spend~~vendors ~~capital~~primarily ~~on:~~for inventory purchases, operating expenses, and professional and technical services incurred in the ordinary course of business.

1.	marketing and brand promotion of UMeLook; and
2.	sales and marketing activities related to establishing collaborative, licensing and distribution agreements for our drug products.

Accrued liabilities and other payables consist primarily of accrued operating expenses and advances from non-related parties. As of December 31, 2025 and September 30, 2025, the balance included advances from a non-related individual of $177,050 and $173,050, respectively. These advances are unsecured, non-interest bearing, and payable on demand.

~~The~~NOTE ~~inability~~5. toRELATED ~~raise~~PARTY ~~capital~~TRANSACTIONS ~~would~~AND ~~have a material adverse effect on the Company.~~BALANCES

~~CERTAIN~~The ~~FACTORS~~Company ~~THAT~~has ~~MAY~~relationships ~~AFFECT~~with ~~FUTURE~~certain ~~RESULTS~~directors, executive officers, and significant shareholders that are considered related parties under ASC Topic 850.

Certain of the information contained in this document constitutes “forward-looking statements”, including but not limited to those with respect to the future revenues, our development strategy, involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks and uncertainties associated with a drug delivery company which has not successfully commercialized our first product, including a history of net losses, unproven technology, lack of manufacturing experience, current and potential competitors with significant technical and marketing resources, need for future capital and dependence on collaborative partners and on key personnel. Additionally, we are subject to the risks and uncertainties associated with all drug delivery companies, including compliance with government regulations and the possibility of patent infringement litigation, as well as those factors disclosed in our documents filed from time to time with the United States Securities and Exchange Commission.

Name of Related Party	Relationship
Michael Lee	Director and Chief Executive Officer of the Company
Winfield, Yongbiao Ding	Chief Financial Officer of the Company
Ford Moore	Director of the Company
Dave Milroy	Director of the Company
First Scion Investments Limited	Shareholder (>5% shareholding)

~~ITEM~~During 3the three months ended December 31, 2025, the Company completed a related-party transfer of ownership of Dagola Hong Kong Limited from the Chief Executive Officer to the Company, after which Dagola Hong Kong Limited became a wholly owned subsidiary. ~~QUANTITATIVE~~Dagola ~~AND~~Hong ~~QUALITATIVE~~Kong ~~DISCLOSURES~~Limited ~~ABOUT~~is ~~MARKET~~the ~~RISK~~sole shareholder of Guangzhou Duokanglong Special Medical Nutrition Technology Co., Ltd., which accordingly became an indirect wholly owned subsidiary of the Company upon the transfer.

~~Not~~12 ~~required~~Table ~~for~~of ~~smaller reporting companies.~~Contents

17Balances Due to Related Parties

~~ITEM~~Amounts 4due to related parties represent non-trade advances, unpaid compensation and expense reimbursements from directors and a significant shareholder arising in the ordinary course of supporting the Company’s operations. ~~CONTROLS~~These ~~AND~~balances ~~PROCEDURES~~are unsecured, non-interest bearing, and payable on demand.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our “disclosure controls and procedures,” as such term is defined in Rules 13a-15e promulgated under the Exchange Act as of this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report to provide reasonable assurance that material information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Related Party	Balance as of December 31, 2025		Balance as of September 30, 2025
Michael Lee (CEO & Director)	$	205,141	$	154,647
Ford Moore (Director)	$	49,000	$	49,000
First Scion Investments Limited (Shareholder)	$	75,722	$	75,722
Total due to related parties	$	329,863	$	279,369

~~Management~~Balances ~~is aware that there is a lack of segregation of certain duties at the Company~~ due to ~~the~~Mr. ~~small~~Moore ~~number of employees with responsibility for general administrative~~ and ~~financial~~First ~~matters.~~Scion ~~This~~Investments ~~constitutes~~Limited awere ~~deficiency~~carried inforward ~~financial~~from ~~reporting.~~prior ~~However,~~periods ~~at this time, management has decided that considering the employees involved~~ and ~~the~~remain ~~control procedures in place~~unsecured, the risks associated with such lack of segregation of duties are insignificant and the potential benefits of adding additional employees to clearly segregate duties do not justify the additional expenses associated with such increases. Management will periodically renon-~~evaluate~~interest ~~this situation. If the volume of business increases and sufficient capital is secured~~bearing, ~~it is the Company’s intention to further increase staffing to mitigate the current lack of segregation of duties within the general, administrative~~ and ~~financial~~payable ~~functions~~on demand.

~~Management~~No isother ~~responsible~~material ~~for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a~~related-~~15(f),~~party ~~and~~transactions ~~for~~occurred ~~the~~during ~~assessment of~~ the ~~effectiveness~~three ofmonths ~~internal~~ended ~~control~~December ~~over financial reporting. As defined by the Securities and Exchange Commission~~31, internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by our Board, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements in accordance with U2025.~~S. generally accepted accounting principles.~~

~~Our~~NOTE internal control over financial reporting is supported by policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the consolidated financial statements in accordance with U6.S. ~~generally~~COMMITMENTS ~~accepted~~AND accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.CONTINGENCIES

18As of December 31, 2025 and 2024, the Company has no material lease obligations, capital commitments, or contingent liabilities that require accrual or material disclosure under ASC 450-20, Commitments.

~~Changes~~NOTE in7. ~~Internal~~STOCKHOLDERS’ ~~Controls~~EQUITY

~~Management~~The ~~has~~Company ~~evaluated~~is ~~the~~authorized ~~effectiveness~~to ofissue ~~the~~up ~~disclosure~~to ~~controls and procedures as of December 31~~250, ~~2012. Based on such evaluation~~000,000 ~~management~~ordinary ~~has~~shares ~~concluded~~with ~~that~~a ~~the~~par ~~disclosure~~value ~~controls~~of ~~and procedures were ineffective for their intended purpose described above~~$0.0001 ~~There~~per ~~were no changes to the internal controls during the quarter ended December 31, 2012 that have materially affected or that are reasonably likely to affect the internal controls~~share.

~~Limitation~~The onCompany ~~the~~did ~~Effectiveness~~not issue any shares of ~~Controls~~common stock during the three months ended December 31, 2025.

AShares control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Such limitations include the fact that human judgment in decision-making can be faulty and that breakdowns in internal control can occur because of human failures, such as simple errors or mistakes or intentional circumvention of the established process.Outstanding

19As of December 31, 2025, the Company had 114,785,005 shares of common stock issued and outstanding. There was no change from September 30, 2025.

~~PART~~NOTE II8. ~~OTHER~~ ~~INFORMATION~~INCOME TAXES

~~ITEM~~Prior 1to –October ~~LEGAL~~2, ~~PROCEEDINGS~~2025, the Company was incorporated in the British Virgin Islands and generally was not subject to income taxes. On October 2, 2025, the Company completed its redomiciliation to the United States (Delaware) and became subject to U.S. federal and applicable state income taxes.

OnFor ~~June 29, 2011, we filed an action in~~ the ~~Ontario~~three ~~Superior~~months ~~Court~~ended ofDecember ~~Justice~~31, ~~Case~~2025 Noand ~~CV-11-42969~~2024, ~~captioned~~the ~~AlphaRx~~Company ~~Inc.~~recorded vno ~~Joseph~~provision ~~Schwarz,~~for ~~Michael~~income ~~Weisspapir~~taxes, ~~and~~primarily ~~Nanoessentials~~due ~~Inc~~to ~~for~~operating ~~conversion~~losses and ~~misuse~~the offull ~~our~~valuation ~~intellectual~~allowance ~~property~~against ~~and~~deferred ~~breach~~tax ~~of fiduciary duty~~assets. ~~The Claim was settled on January 11, 2012.~~

~~ITEM~~The 1ACompany –recognizes ~~RISK~~interest ~~FACTORS~~and penalties related to uncertain tax positions, if any, as a component of income tax expense. As of December 31, 2025 and September 30, 2025, the Company had no accrued interest or penalties related to uncertain tax positions.

The ~~following~~Company ~~risk~~files ~~factors~~income ~~should~~tax bereturns ~~read carefully~~ in ~~connection with evaluating our business and~~ the ~~forward-looking~~United ~~statements~~States ~~that we make in this Report~~ and ~~elsewhere~~applicable ~~(including~~foreign ~~oral statements) from time to time~~jurisdictions. ~~Any~~Tax ofyears ~~the~~remain ~~following~~subject ~~risks~~to ~~could~~examination ~~materially~~by ~~and~~taxing ~~adversely~~authorities ~~affect~~in ~~our~~accordance ~~business,~~with ~~our operating results, our financial condition and~~ the ~~actual~~respective ~~outcome~~statutes of ~~matters as to which forward-looking statements are made in this Report~~limitation.

~~Risks~~NOTE ~~Related~~9. toSEGMENT ~~Our Drug Business~~REPORTING

WeThe ~~face~~Company ~~intense~~applies ~~competition~~ASC Topic 280, Segment Reporting, in ~~the~~determining ~~pharmaceutical~~its reportable segments. An operating segment is a component of the business, for which discrete financial information is available and ~~our~~regularly ~~failure~~reviewed toby ~~compete~~the ~~effectively~~Company’s ~~would~~Chief ~~decrease~~Operating ~~our~~Decision ~~ability~~Maker to(“CODM”) ~~generate~~in ~~meaningful~~assessing ~~revenues~~performance ~~from~~and ~~our~~allocating ~~products~~resources.

~~The~~13 ~~pharmaceutical~~Table ~~business is highly competitive and is affected by new technologies, governmental regulations, health care legislation, availability~~ of financing, litigation and other factors. We are subject to competition from numerous other entities that currently operate or intend to operate in the industry. These include companies that are engaged in the development of colloidal drug delivery technologies and products as well as other manufacturers that may decide to undertake in-house development of these products. Many of our competitors have more extensive experience than we have in conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. Many competitors also have competing products that have already received regulatory approval or are in late-stage development, and may have collaborative arrangements in our target markets with leading companies and research institutions. Our competitors may develop or commercialize more effective, safer or more affordable products, or obtain more effective patent protection, than we are able to develop, commercialize or obtain. As a result, our competitors may commercialize products more rapidly or effectively than we do, which would adversely affect our competitive position, the likelihood that our products will achieve market acceptance, and our ability to generate meaningful revenues from our products.Contents

WeManagement has determined that the Company operates as one operating and reportable segment, as its operations are ~~subject~~focused toon ~~industry~~the development, marketing, and ~~government~~sale ~~regulation~~of functional nutrition and DAG-based cooking oil products under the DAGola® brand. The CODM reviews financial results on a consolidated basis, and discrete financial information is not prepared for separate business lines.

~~All~~For ofthe ~~our~~three ~~products,~~months ~~clinical~~ended ~~trials~~December 31, ~~and~~2025, ~~certain~~revenues ~~research~~were ~~and~~generated ~~development~~primarily ~~initiatives~~from ~~are~~product ~~regulated~~sales bythrough ~~FDA~~online and distribution channels in the United States, ~~and~~with ~~similar~~limited ~~governing~~initial ~~bodies~~revenues generated in ~~Mexico,~~Asia-Pacific ~~China~~late ~~and~~in ~~elsewhere~~the quarter. ~~Any~~For ~~changes~~the inthree ~~regulatory~~months ~~requirements,~~ended ~~depth~~December ~~and~~31, ~~breadth~~2024, ofrevenues ~~clinical~~were ~~trials,~~generated ~~provisions,~~from ~~statutes,~~sales orin ~~regulations~~the ~~could~~United ~~adversely~~States ~~impact~~only. ~~the~~The ~~cost~~Company ~~and~~operates ~~duration~~as ofa ~~our~~single ~~research~~reportable ~~and~~segment; ~~development~~accordingly, ~~product~~no ~~completion~~additional ~~and~~segment ~~related~~disclosures ~~operations~~are presented.

20NOTE 10. CONCENTRATIONS OF RISK

~~Our~~The ~~competitors~~Company ~~may~~is exposed to various risks arising from its business operations. The primary risks include ~~large~~foreign ~~pharmaceutical~~currency ~~companies~~risk, ~~with~~liquidity ~~superior~~risk, ~~resources~~product-liability exposure, and concentration risks related to customers and suppliers.

~~We are engaged in~~ (a) ~~rapidly~~Foreign ~~changing~~Currency ~~and~~Exchange ~~highly~~Rate competitive field. To date, we have concentrated our efforts primarily on one pharmaceutical product -- Indaflex – for treating osteoarthritis and other inflammatory indications. Like the market for any pharmaceutical product, the market for treating arthritis and these other indications has the potential for rapid, unpredictable and significant technological change. Competition is intense from specialized biotechnology companies, major pharmaceutical and chemical companies and universities and research institutions. We currently have no products approved for sale in the U.S. If we are successful in obtaining approval for one of our products, our future competitors will have substantially greater financial resources, research and development staffs and facilities, and regulatory experience than we do. Major companies in the field of osteoporosis treatment include Novartis, Wyeth, Merck, Eli Lilly, Aventis, and Procter & Gamble Co. Any one of these potential competitors could, at any time, develop products or a manufacturing process that could render our technology or products non-competitive or obsolete.Risk

~~Our~~The ~~prior~~Company’s ~~clinical~~reporting ~~trials~~currency ~~evaluating~~is ~~Indaflex for~~the ~~Osteoarthritis~~U.S. ofdollar. Substantially all expenses were denominated in U.S. dollars during the ~~knee~~three ~~failed~~months toended ~~meet~~December ~~all~~31, 2025 and 2024. During the quarter ended December 31, 2025, the Company commenced limited sales activity in Asia, and a significant majority of ~~their~~the ~~primary~~Company’s ~~endpoints~~revenue for the period was generated from customers in China, resulting in certain transactions denominated in Renminbi. The Company also maintains a Hong Kong subsidiary, which is currently inactive and ~~there~~does ~~can~~not behave nosignificant ~~assurance~~transactions ~~this~~denominated ~~product~~in ~~will~~foreign becurrencies. ~~approved~~While ~~for~~the ~~marketing~~Company is exposed to foreign currency exchange risk related to Renminbi-denominated transactions, such exposure is not considered material at this time.

In(b) ~~October 2007,~~Liquidity our Phase 2 Canadian trials evaluating Indaflex for Osteoarthritis of the knee failed to meet all of their primary endpoints. However, additional analyses demonstrated that patients with moderate to severe pain demonstrated improvements in pain outcomes compared to placebo- and vehicle-treated patients. While these improvements involved only a small subset of patients, the data were robust, showing clinically meaningful improvements. Based on the guidance from Chinese regulatory consultants, we expect to initiate a pivotal human trial for Indaflex in China in mid-2014. The trial will be known as PAIN 3. There can be no assurance the results of the PAIN 3 trial will demonstrate the product candidate is sufficiently safe and effective to obtain Chinese approval for marketing. We will incur significant additional expenses and will not know for at least one to two years whether the drug is safe and effective such that it could be approved for marketing. Clinical development is a long, expensive and uncertain process and is subject to delays. The positive or encouraging results of prior clinical trial are not necessarily indicative of the results we will obtain in later clinical trials. Accordingly, our PAIN 3 trial may not demonstrate that Indaflex is effective for Osteoarthritis. In addition, data obtained from pivotal clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.Risk

IfThe weCompany ~~are~~has ~~unable~~incurred torecurring ~~obtain~~operating orlosses ~~maintain~~and ~~regulatory~~has ~~approval,~~a weworking ~~will~~capital bedeficiency. ~~limited~~The inCompany’s ~~our~~ ability to ~~commercialize~~meet ~~our~~its ~~products,~~obligations depends on generating additional revenues and ~~our~~obtaining ~~business~~external ~~will~~financing. beThese ~~harmed~~conditions are described further in the Going Concern note to the condensed consolidated financial statements.

~~The~~(c) ~~regulatory~~Product ~~process~~Liability is expensive and time consuming. Even after investing significant time and expenditures on clinical trials, we may not obtain regulatory approval of our product candidates. Data obtained from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval, and the regulatory agency may not agree with our methods of clinical data analysis or our conclusions regarding safety and/or efficacy. Significant clinical trial delays would impair our ability to commercialize our products and could allow our competitors to bring products to market before we do. In addition, changes in regulatory policy for product approval during the period of product development and regulatory agency review of each submitted new application may cause delays or rejections. Even if we receive regulatory approval, this approval may entail limitations on the indicated uses for which we can market a product.Exposure

~~Further,~~The ~~with~~Company ~~respect~~records toaccruals ~~our~~for ~~approved products, once regulatory approval is obtained, a marketed~~ product-related ~~and~~claims ~~its~~when ~~manufacturer~~losses are ~~subject~~probable toand ~~continual~~reasonably ~~review~~estimable. ~~The discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product~~Historically, ~~manufacturer or manufacturing facility, including withdrawal of the~~ product ~~from~~returns ~~the~~and ~~market.~~claims ~~Manufacturers~~have ofnot ~~approved~~been ~~products are also subject to ongoing regulation, including compliance with regulations governing current Good Manufacturing Practices (cGMP)~~material. ~~Failure~~No toproduct ~~comply~~liability ~~with~~accruals ~~manufacturing~~were ~~regulations~~recorded ~~can~~as ~~result in, among other things, warning letters, fines, injunctions, civil penalties, recall or seizure~~ of ~~products,~~December ~~total or partial suspension of production~~31, ~~refusal~~2025 ~~of the government to renew marketing applications~~ and ~~criminal~~September ~~prosecution~~30, 2025.

21d) Customer / Revenue Concentration

~~Our~~The ~~success~~Company ~~depends~~generates ~~upon~~revenue ~~our~~through ~~ability~~a tolimited ~~protect~~number ~~our~~of ~~intellectual~~distribution ~~property~~channels, ~~rights~~including online marketplace platforms and distribution partners.

WeFor ~~filed applications for U.S. patents relating to proprietary drug delivery technologies and formulations that we have invented in~~ the ~~course~~three ofmonths ~~our~~ended ~~research.~~December ~~To date~~31, three U.S. patents have been issued and other applications are pending. We have also made patent application filings in selected foreign countries. We face the risk that any of our pending applications will not issue as patents. In addition2025, ~~our~~one ~~patents~~distribution ~~may~~partner beaccounted ~~found to be invalid or unenforceable. Our business is also subject to the risk that our issued patents will not provide us with significant competitive advantages if,~~ for ~~example,~~approximately a98% ~~competitor~~of ~~were to independently develop or obtain similar or superior technologies. To~~ the ~~extent~~Company’s wetotal ~~are unable to protect our patents and patent applications, our investment in those technologies may not yield the benefits that we expect~~revenue. We ~~also~~No rely on trade secrets to protect our inventions. Our policy is to include confidentiality and non-disclosure obligations in all research contracts, joint development agreements and consulting relationships that provide access to our trade secrets and other ~~know-how.~~individual ~~However,~~customer ~~parties with confidentiality obligations could breach their agreements causing us harm. If a confidentiality~~ or ~~non-disclosure~~channel ~~obligation~~represented ~~were~~10% ~~to be breached, we may not have the financial resources necessary for a legal challenge. If licensees, consultants~~ or ~~other~~more ~~third parties use technological information independently developed by them or by others in the development~~ of ~~our~~total ~~products,~~revenue ~~disputes~~for ~~may arise from~~ the ~~use of this information and as to the ownership rights to products developed using this information~~period. These disputes may not be resolved in our favour. We are not aware of infringing on any third party’s patents, nor are we aware of any third party infringing on any of our patents or patent applications.

~~Our~~For ~~technology,~~the ~~clinical~~three ~~trials~~months ended December 31, or2024, ~~products~~substantially ~~could~~all ~~give~~of ~~rise~~the toCompany’s ~~product~~revenue ~~liability~~was ~~claims~~generated through a single online marketplace channel.

~~Our~~Because ~~business exposes us to~~ the ~~risk~~Company ofcurrently ~~product~~relies ~~liability~~on ~~claims that are~~ a ~~part~~limited ofnumber ~~human testing, manufacturing and sale~~ of ~~pharmaceutical~~significant ~~products.~~distribution ~~The administration of drugs to humans~~channels, ~~whether~~the inloss ~~clinical~~of ~~trials~~a orkey ~~commercially,~~partner ~~can result in product liability claims even if our products are not actually at fault for causing an injury. Furthermore, our products may cause,~~ or ~~may~~a ~~appear~~material toreduction cause, adverse side effects or potentially dangerous drug interactions that we may not learn about or understand fully until the drug is actually manufactured and sold. Product liability claims can be expensive to defend and may result in ~~large~~sales ~~judgments~~through ~~against~~such ~~us.~~channel ~~Even~~could ifadversely aaffect ~~product liability claim is not successful,~~ the ~~adverse~~Company’s ~~publicity,~~revenues ~~time,~~ and ~~expense~~operating ~~involved in defending such a claim may interfere with our business~~results. We may not have sufficient resources to defend against or satisfy these claims. Even though our licensees are required to have product liability insurance we may still be subject to product liability claims.

~~Risks~~(e) ~~Related~~Geographic ~~to Our Digital Media Business~~Concentration

WeThe ~~have~~Company agenerates ~~short~~revenue ~~operating~~from ~~history~~multiple ingeographic ~~a new and unproven market, which makes it difficult to evaluate our future prospects and may increase the risk that we will not be successful~~markets.

We14 ~~entered~~Table the online video business in August 2012 when we acquired UMeLook Holdings Limited. However, UMeLook only have a short operating history in this new and unproven market that may not develop as expected, if at all. This short operating history makes it difficult to effectively assess our future prospects. You should consider our business and prospects in light of ~~the risks and difficulties we encounter in this rapidly evolving market.~~Contents

22For the three months ended December 31, 2024, 100% of the Company’s total revenue was generated from sales in the United States.

WeFor ~~operate~~the inthree amonths ~~highly~~ended ~~competitive~~December ~~market~~31, ~~and~~2025, weapproximately ~~may~~98% ~~not~~of betotal ~~able~~revenue towas ~~compete~~generated ~~successfully~~from ~~against~~sales ~~our~~in ~~competitors~~China, with the remainder generated from the United States.

WeChanges ~~face significant competition, primarily from those companies that operate online video websites~~ in ~~China,~~economic ~~which our management estimates to currently number over one hundred. A large number of independent online video sites~~conditions, ~~such~~regulatory ~~as Youku.com and Tudou.com~~environments, ~~compete~~trade ~~against us. In addition~~policies, ~~Chinese Internet portals, including Sina.com, Sohu.com and Baidu.com, and some of China’s major TV networks, such as China Central Television,~~ or ~~CCTV,~~market ~~Phoenix~~demand ~~Satellite TV and Hunan Satellite TV, which have longer operating histories and more experience~~ in ~~attracting~~these ~~and~~regions ~~retaining~~could ~~users~~adversely ~~and~~affect ~~managing customers than we do, have launched their own video businesses. We also face competition from Internet video streaming platforms based on~~ the ~~P2P~~Company’s technology, such as PPS and PPTV. We compete with these companies for users and advertisers. Our competitors may compete with us in a variety of ways, including by conducting brand promotions and other marketing activities and making acquisitions. In addition, certain online video websites may continue to derive their revenues ~~from providing content that infringes third-party copyright~~ and may not monitor their websites for any such infringing content. As a result, we may be placed at a disadvantage to some of these websites that do not incur similar costs as we do with respect to content monitoring. Some of our competitors have a longer operating history and significantly greater financial resources than we do, and in turn may be able to attract and retain more users and advertisers. If any of our competitors achieves greater market acceptance than we do or is able to offer more attractive online video content, our user traffic may decrease and our market share may decrease, which may result in a loss of advertisers and have a material and adverse effect on our business, financial condition and results of operations.

In(f) ~~addition,~~Supplier Internet streaming of content represents only one of many existing and potential new technologies for viewing video. Many users maintain simultaneous relationships with multiple video providers and can easily shift from one provider to another. For example, users may subscribe to cable, buy a DVD, and download a movie from Apple iTunes or other sources, or some combination thereof. New competitors may be able to launch new businesses at a relatively low cost.Concentration

WeThe ~~also~~Company ~~face~~relies competition from other types of advertising media, such as newspapers, magazines, yellow pages, billboards and other forms of outdoor media, television and radio. Most large companies in China allocate, and will likely continue to allocate, most of their marketing budgets to traditional advertising media and only a small portion of their budgets to online marketing and other forms of advertising media. If these companies do not devote a larger portion of their marketing budgets to online marketing services provided by our online video business, or if our existing customers reduce the amount they spend on ~~online~~third-party ~~marketing,~~suppliers ~~our~~for ~~results~~specialized ofproduct ~~operations~~inputs and ~~future~~finished ~~growth prospects could be adversely affected~~goods.

~~The~~For ~~online~~the ~~video~~three ~~industry~~months inended ~~China~~December ~~and~~31, ~~user~~2025, ~~acceptance~~one supplier accounted for approximately 99% of ~~our~~total ~~online~~cost ~~video~~of ~~content~~sales. ~~may~~No ~~not~~other ~~grow~~individual assupplier ~~quickly~~represented as10% ~~expected~~or more of total cost of sales for the period. This supplier is the Company’s strategic manufacturing partner for DAG oil, which ~~may~~is ~~adversely~~a ~~affect~~specialized ~~our~~ingredient ~~revenues~~used ~~and~~in ~~business~~the ~~prospects~~Company’s products.

~~Our~~For ~~business prospects depend on~~ the ~~continuing~~three ~~development~~months ofended ~~the~~December ~~online video industry in China. As an emerging industry~~31, ~~China’s online video industry has experienced substantial growth in recent years in terms of both users and content. We cannot assure you~~2024, ~~however, that~~ the ~~online~~Company ~~video~~relied ~~industry~~on ~~will~~a ~~continue~~single tosupplier ~~grow~~for assubstantially ~~rapidly~~all ~~as it has in the past. With the development~~ of ~~technology,~~its ~~new~~cost ~~forms~~ of ~~media may emerge and render online video websites less attractive to users~~sales. Growth of the online video industry is affected by numerous factors, such as users’ general online video experience, technological innovations, development of Internet and Internet-based services, regulatory changes, especially regulations affecting copyrights, and the macroeconomic environment. If the online video industry in China does not grow as quickly as expected or if we fail to benefit from such growth by successfully implementing our business strategies, our user traffic may decrease and our business and prospects may be adversely affected.

23Due to the specialized nature of DAG oil production, the Company currently relies on this strategic partner as its primary source of supply. While additional qualified producers may exist, transitioning to an alternative supplier would require technical validation, commercial qualification, and regulatory and quality review, which could result in temporary supply disruption and margin variability.

WeDisruption ~~operate~~ in athese ~~rapidly~~supplier ~~evolving~~relationships ~~industry.~~could Ifadversely weaffect ~~fail to keep up with the technological developments and users’ changing requirements, our business, results of~~ operations ~~and prospects may be materially and adversely affected~~.

~~The~~NOTE ~~online video industry is rapidly evolving and subject to continuous technological changes and changes in industry standards~~11. ~~Our~~SUBSEQUENT success will depend on our ability to keep up with the changes in technology and user behavior resulting from the technological developments. For example, the development of broadband enabled the enjoyment of high definition videos online. In addition, the number of people accessing the Internet via devices other than personal computers, including mobile phones and other hand-held devices, has increased in recent years. With the introduction of 3G mobile services by all three mobile carriers in China in 2009, we expect this trend to continue. If we do not adapt our products and services to such changes in an effective and timely manner, we may suffer from a decreased user traffic, which may result in a reduced number of advertisers using our online advertising services. Furthermore, changes in technologies may require substantial capital expenditures in product development as well as in modification of products, services or infrastructure. Failure in keeping up with technological development may result in our products and services being less attractive, which in turn, may materially and adversely affect our business, results of operations and prospects.EVENTS

IfIn weaccordance ~~fail~~with toASC ~~continue~~Topic to855, ~~anticipate~~“Subsequent ~~user~~Events,” ~~preferences~~which ~~and~~establishes ~~provide~~the ~~products~~standards ~~and~~for ~~services~~accounting tofor ~~attract~~events occurring after the balance sheet date but before the consolidated financial statements are issued, the Company evaluated all events and ~~retain~~transactions ~~users~~that occurred after December 31, we2025, ~~may~~through ~~not~~the bedate ~~able~~the toaudited ~~generate~~consolidated ~~sufficient~~financial ~~user~~statements ~~traffic~~were available to ~~remain~~be ~~competitive~~issued. Based on this evaluation, management identified the following subsequent events requiring disclosure:

~~Our~~On ~~success~~January ~~depends~~16, on2026, ~~our~~Verdant ~~ability~~Sustainable toFuel ~~generate~~Sdn. ~~sufficient~~Bhd. ~~user~~was ~~traffic~~incorporated ~~through~~in ~~provision~~Malaysia. ofThe ~~attractive~~entity ~~products~~was ~~and~~initially ~~services.~~formed Toby ~~attract~~the ~~and~~Company’s ~~retain~~Chief ~~users~~Executive Officer and ~~compete~~was ~~against~~subsequently ~~our~~transferred ~~competitors, we must continue~~ to ~~offer~~the ~~high-quality~~Company ~~content~~in ~~that provides our users with~~ a ~~satisfactory online video experience. To this end, we must continue to produce new in~~related-~~house~~party ~~content and encourage more UGC~~transaction, ~~while~~after ~~balancing~~which ~~the~~it ~~value~~became ofa ~~each~~wholly ~~type~~owned ofsubsidiary. ~~content~~Verdant toSustainable ~~our~~Fuel ~~advertising~~Sdn. ~~services~~Bhd. ~~For~~was ~~example,~~established ~~with~~to ~~UGC,~~support ~~users can upload and share their own videos and spend a longer time on our website, and a “community~~early-~~like”~~stage ~~environment~~evaluation ~~enhances~~activities ~~users’~~related ~~loyalty~~ to ~~our~~renewable ~~website~~fuel and ~~such~~sustainable ~~network~~aviation ~~effect~~fuel ~~broadens~~feedstock ~~advertisers’~~initiatives ~~reach of audience;~~ and ~~with~~is ~~our in~~pre-~~house~~commercial. ~~productions,~~As weof ~~tailor~~the ~~such~~issuance ~~content~~date toof ~~users’ preferences based on our industry experience and combine~~ these ~~productions~~condensed ~~with~~consolidated ~~targeted~~financial ~~advertising services such as product placements~~statements, ~~which benefits both~~ the ~~users~~entity ~~and~~has ~~our~~not ~~advertisers~~generated revenue.

~~Based~~On onJanuary 19, 2026, the ~~feedback~~Company onapproved ~~our~~the ~~website~~conversion ~~design~~of ~~and~~advances ~~our~~previously ~~statistics~~provided ~~regarding~~by ~~users’~~the ~~watching~~Chief ~~behavior,~~Executive weOfficer ~~keep~~and ~~developing~~a ~~new~~director ~~website~~into ~~features~~shares ~~that~~of ~~appeal~~the toCompany’s ~~users,~~common ~~such~~stock asat ~~designing~~a ~~more~~conversion ~~user-friendly~~price ~~content~~of ~~searching~~$0.25 ~~tools,~~per ~~creating~~share. ~~additional~~Michael ~~interactive~~Lee, ~~social~~the ~~functions~~Company’s orChief ~~offering~~Executive ~~better~~Officer ~~website~~and ~~compatibility~~a ~~with~~director, ~~new~~converted ~~Internet-enabled~~$154,647 ~~devices.~~of Weadvances ~~need~~into to618,588 ~~continuously~~shares ~~anticipate~~of ~~user~~common ~~preferences~~stock, and ~~industry~~Ford ~~changes~~Moore, ~~and~~a ~~respond~~director, toconverted ~~such~~$49,000 ~~changes~~of inadvances ainto ~~timely~~196,000 ~~and~~shares ~~effective~~of ~~manner~~common stock. IfIn weaggregate, ~~fail~~$203,647 toof ~~cater~~related-party toadvances ~~the~~were ~~needs~~converted ~~and~~into ~~preferences~~814,588 shares of ~~our~~common ~~users~~stock. ~~and,~~The asconversion areduced ~~result,~~amounts ~~fail~~due to ~~deliver~~related ~~satisfactory~~parties ~~user~~and ~~experience,~~increased westockholders’ ~~may~~equity. ~~suffer~~The ~~from~~transaction ~~reduced~~was ~~user~~approved ~~traffic~~by ~~and~~the ~~our~~Board ~~business~~of Directors and ~~results~~was exempt from registration under the Securities Act of ~~operations~~1933, ~~may~~as beamended, ~~materially~~pursuant to Section 4(a)(2) and/or ~~adversely~~Regulation ~~affected~~D thereunder.

~~The~~On ~~success~~January of21, ~~our~~2026, ~~business~~following ~~depends~~the onCompany’s ~~our~~previously ~~ability~~completed redomiciliation to ~~maintain~~Delaware, FINRA implemented successor issuer recognition, assignment of a new CUSIP number, and ~~enhance~~a ~~our~~change ~~brand~~in the Company’s trading symbol to UMEW. These actions did not affect the Company’s consolidated financial position or results of operations.

WeThe ~~believe~~Company ~~that~~did ~~maintaining~~not ~~and~~identify ~~enhancing~~any ~~our~~other ~~UMeLook~~subsequent ~~brand~~events isthat ofrequire ~~significant~~adjustment ~~importance~~ to ~~the~~or ~~success~~disclosure ~~of our business. Since the online video market is highly competitive, a well-recognized brand is critical to increasing our user base and,~~ in ~~turn, enhancing our attractiveness to advertisers. We believe that~~ the ~~importance~~condensed ofconsolidated ~~brand~~financial ~~recognition will increase as the number of Internet users in China grows~~statements. In order to attract and retain Internet users and advertisers, we may need to substantially increase our expenditures for creating and maintaining brand loyalty. Our success in promoting and enhancing our brand, as well as our ability to remain competitive, will also depend on our success in offering high-quality content, features and functionality. If we fail to promote our brand successfully or if visitors to our website or advertisers do not perceive our content and services to be of high quality, we may not be able to continue growing our business and attracting users and advertisers.

2415 Table of Contents

~~Disruption~~ITEM or2. ~~failure~~MANAGEMENT’S ofDISCUSSION ~~our~~AND ~~systems~~ANALYSIS ~~could~~OF ~~impair~~FINANCIAL ~~our~~CONDITION ~~users’~~AND ~~online~~RESULTS ~~video~~OF ~~experience and adversely affect our reputation.~~OPERATIONS

~~Our~~The ~~ability~~information tocontained ~~provide~~in ~~users~~this ~~with~~Quarterly aReport ~~high-quality~~on ~~online~~Form ~~video~~10-Q ~~experience~~updates ~~depends on~~ the ~~continuous~~information ~~and~~contained ~~reliable operation of our systems. We cannot assure you that we will be able to procure sufficient bandwidth~~ in athe ~~timely~~Company’s ~~manner~~Annual orReport on ~~acceptable~~Form ~~terms~~20-F orfor atthe ~~all.~~fiscal ~~Failure~~year toended doSeptember so30, ~~may~~2025. ~~significantly~~This ~~impair~~discussion ~~user~~should ~~experience~~be onread ~~our~~together ~~website~~with ~~and decrease~~ the ~~overall~~audited ~~effectiveness~~consolidated offinancial ~~our~~statements ~~website to both users~~ and ~~advertisers.~~related ~~Disruptions,~~notes ~~failures,~~included ~~unscheduled service interruptions or a decrease~~ in ~~connection~~that ~~speeds could hurt user experience and our reputation~~report, ~~causing~~as ~~our~~well ~~users and advertisers to switch to our competitors’ websites. Our systems and video content delivery network, or CDN, are vulnerable to damage or interruption~~ as athe ~~result~~unaudited ofcondensed ~~fires,~~consolidated ~~floods,~~financial ~~earthquakes,~~statements ~~power losses, telecommunications failures, undetected errors in software, computer viruses, hacking~~ and ~~other~~related ~~attempts~~notes toincluded ~~harm~~elsewhere ~~our systems.. Since we host our servers at third-party Internet data centers, any natural disaster or unexpected closure of Internet data centers operated by third-party providers may result~~ in ~~lengthy~~this ~~service~~Form ~~interruptions. If we experience frequent or persistent service disruptions, whether caused by failures of our own systems or those of third~~10-~~party service providers, our users’ experience may be negatively affected, which in turn, may have a material and adverse effect on our reputation~~Q. ~~We cannot assure you that we will be successful in minimizing the frequency or duration of service interruptions~~

~~Undetected~~This ~~programming~~Management’s ~~errors~~Discussion ~~could~~and ~~adversely~~Analysis ~~affect~~of ~~user~~Financial ~~experience~~Condition and Results of Operations contains forward-looking statements within the ~~market~~meaning ~~acceptance~~of the Private Securities Litigation Reform Act of ~~our~~1995. ~~video~~These ~~programs,~~forward-looking ~~which~~statements ~~may~~are ~~materially~~based on current expectations and ~~adversely~~assumptions ~~affect~~and ~~our~~involve ~~business~~risks and uncertainties that could cause actual results ofto ~~operations~~differ materially from those expressed or implied by such statements. Forward-looking statements are typically identified by words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate,” or similar expressions.

~~The~~Forward-looking ~~video~~statements ~~programs~~speak ~~on our website may contain programming errors that may~~ only ~~become~~as ~~apparent~~of ~~after~~the ~~their~~date ~~release.~~of Wethis ~~receive~~Quarterly ~~user feedback in connection with programming errors affecting their user experience from time to time, and such errors may also come to our attention during our monitoring process~~Report. WeThe ~~generally~~Company ~~have~~undertakes ~~been~~no ~~able~~obligation to ~~resolve~~update ~~such~~any ~~programming~~forward-looking ~~errors in a timely manner. However~~statements, weexcept ~~cannot~~as ~~assure~~required ~~you~~by ~~that~~law. weReaders ~~will~~are becautioned ~~able~~not to ~~detect~~place ~~and~~undue ~~resolve~~reliance ~~all~~on these ~~programming~~forward-looking ~~errors effectively~~statements. Undetected audio or video programming errors or defects may adversely affect user experience and cause our advertisers to reduce their use of our services, any of which could materially and adversely affect our business and results of operations.

WeCompany may be exposed to intellectual property infringement and other claims, including claims based on content posted on our website, which could be time-consuming and costly to defend and may result in substantial damage awards and/or court orders that may prevent us from continuing to provide certain of our existing services.Overview

~~Our~~UMeWorld ~~success depends, in large part, on our ability to operate our business without infringing third-party rights, including third-party intellectual property rights~~Inc. ~~Internet~~is ~~companies, technology and media industries own, and are seeking to obtain,~~ a ~~large~~holding ~~number~~company offocused ~~patents,~~on ~~copyrights,~~functional ~~trademarks~~nutrition and ~~trade~~health ~~secrets,~~ and ~~they~~wellness are frequently involved in litigation based on allegations of infringement or other violations of intellectual property rights or other related legal rights. There may be patents issued or pending that are held by others that cover significant aspects of our technologies, products~~, business methods or services~~. WeFollowing ~~may~~its beexit ~~subject~~from ~~to claims for defamation, negligence, infringement of third-party copyright and other rights, such as privacy and image rights, or other claims based on~~ the ~~nature~~education ~~or content of videos or our users on our websites. Such claims, with or without merit, may cause us to incur significant costs and liabilities and could materially and adversely affect our~~ business, ~~and also result~~ in ~~diversion~~2021, of the ~~attention~~Company ofrepositioned ~~our~~its ~~management~~operations ~~and~~toward ~~our~~DAG-based ~~financial~~cooking ~~resources~~oil and ~~negative~~related ~~publicity~~products onmarketed ~~our~~under ~~brand and reputation. In addition, third parties may make claims against us for losses incurred in reliance on~~ the ~~information~~DAGola® onbrand ~~our~~through ~~websites.~~its Wewholly doowned ~~not carry any liability insurance covering such risks. Due to the significant number of videos uploaded by users~~subsidiary, weDagola ~~may not be able to identify all content that may infringe on third-party rights~~Inc. ~~Thus~~, ~~our~~a ~~failure~~Wyoming ~~to identify unauthorized videos posted on our website may subject us to, and may continue to subject us to, claims of infringement on third-party intellectual property rights or other rights~~corporation.

25The Company’s products are sold primarily through online marketplace platforms and direct-to-consumer channels in the United States. During the quarter ended December 31, 2025, the Company began limited initial sales activity in the Asia-Pacific region through its Hong Kong and People’s Republic of China subsidiaries.

~~Regulation~~Dagola ~~and~~Hong ~~censorship~~Kong ofLimited ~~information~~serves ~~disseminated~~as ~~over~~a ~~the~~regional ~~Internet~~holding inentity, ~~China~~and ~~may~~its ~~adversely~~wholly ~~affect~~owned ~~our~~subsidiary, ~~business~~Guangzhou ~~and~~Duokanglong ~~subject~~Special usMedical toNutrition ~~liability~~Technology ~~for~~Co., ~~information~~Ltd., ~~displayed~~supports onregulatory, ordistribution, ~~linked~~and toearly-stage ~~our~~commercial ~~websites~~activities in Mainland China.

~~The~~On ~~PRC~~October ~~government~~2, ~~has~~2025, ~~adopted regulations governing Internet access and~~ the ~~distribution~~Company ofcompleted ~~news~~its ~~and~~redomiciliation ~~other information over the Internet. Under these regulations, Internet content providers and Internet publishers are prohibited~~ from ~~posting or displaying over~~ the ~~Internet~~British ~~content~~Virgin ~~that,~~Islands ~~among~~to ~~other things, violates PRC laws and regulations, impairs~~ the ~~national~~State ~~dignity~~ of ~~China,~~Delaware orand istransitioned ~~reactionary, obscene, superstitious, fraudulent or defamatory. Furthermore, Internet content providers are also prohibited~~ from ~~displaying~~a ~~content~~foreign ~~that~~private ~~may~~issuer beto ~~deemed~~a ~~by relevant government authorities as “socially destabilizing” or leaking “state secrets” of the PRC~~U.S. ~~Failure~~domestic toissuer ~~comply~~for ~~with~~SEC ~~such~~reporting ~~requirements has resulted in the closure of certain websites~~purposes.

~~Although~~The weCompany’s ~~attempt~~strategy tois ~~monitor~~focused ~~the~~on ~~content~~expanding indistribution ~~our websites~~channels, weincreasing ~~are~~product ~~not able to control or restrict the content of other Internet content providers linked to or accessible through our websites~~availability, orand ~~content~~developing ~~generated~~additional orfunctional ~~placed~~nutrition ~~on our websites by our users~~offerings. ToThe ~~the~~Company ~~extent~~continues ~~that PRC regulatory authorities find any content displayed on our websites objectionable, they may require us~~ to ~~limit~~operate orwith ~~eliminate~~a ~~the~~capital-light ~~dissemination~~model ofutilizing ~~such information on our websites. If~~ third-party ~~websites linked to or accessible through our website operate unlawful activities such as online gambling on their websites~~manufacturing, ~~PRC regulatory authorities may require us to report such unlawful activities to relevant authorities and to remove the links to such websites~~packaging, or they may suspend or shut down the operation of such websites. PRC regulatory authorities may also temporarily block access to certain websites for a period of time for reasons beyond our control. Any of these actions may reduce our user traffic and ~~adversely~~fulfillment ~~affect our business~~providers.

~~Other~~Results ~~Risks~~of ~~Related to Our Business~~Operation

WeFor ~~have~~the ~~significant~~three ~~historical~~months ~~losses~~ended ~~and~~December ~~may~~31, ~~continue~~2025 toand ~~incur losses in the future.~~2024

We have incurred annual operating losses since our inception, our revenues have not been sufficient to sustain our operations. In order to achieve profitability our revenue streams will have to increase and there is no assurance that revenues can increase to such a level. We may never be profitable. Our ability to achieve profitability is affected by various factors, including:Revenue

-Revenue ~~growth~~for of the ~~online~~three ~~video~~months ~~industry~~ended ~~and~~December ~~the~~31, ~~online~~2025 ~~advertising~~was ~~market;~~$147,455, -compared ~~the~~to ~~transition~~$195 ~~from~~for ~~long-form~~the ~~professional~~three ~~content~~months toended ~~short-form~~December ~~user-generated content~~31, or2024. ~~UGC;~~The -increase ~~the~~was ~~continued~~primarily ~~growth~~attributable ~~and~~to ~~maintenance~~fulfillment of ~~our~~an ~~user~~initial ~~base;~~distributor -purchase ~~our~~order ~~efforts~~in toChina ~~sell~~in ~~and~~December ~~market~~2025 ~~our products~~ through ~~licensees,~~the ~~distributors~~Company’s ~~and~~PRC ~~other~~subsidiary, ~~partners;~~which -represented ~~our~~substantially ~~ability~~all toof ~~establish~~quarterly ~~corporate~~revenue. ~~partnerships~~The ~~and~~remainder ~~licensing~~of ~~arrangements;~~revenue -for the ~~time~~quarter ~~and~~was ~~costs~~generated ~~involved~~from sales in ~~obtaining~~the ~~regulatory~~United ~~approvals;~~States -through ~~our ability to control our costs and expenses; and -~~ the ~~continued~~Amazon ~~ability~~marketplace ~~to source investments from our investors~~channel.

26Cost of Revenues and Gross Profit

~~Many~~Cost of ~~these~~revenues ~~factors~~for ~~are~~the ~~beyond~~three ~~our~~months ~~control.~~ended WeDecember ~~may~~31, ~~continue~~2025 towas ~~incur~~$142,913, ~~net~~compared ~~losses~~to in$2,583 for the ~~future~~three ~~due~~months ended December 31, 2024. The increase was primarily attributable to ~~our~~higher ~~continued~~sales ~~investments~~volume in ~~content~~the current quarter, ~~bandwidth~~including ~~and~~fulfillment ~~technology.~~of Ifa wedistributor ~~cannot~~order ~~successfully~~in ~~offset~~China ~~our~~and increased ~~costs~~Amazon ~~with~~channel ansales ~~increase~~ in ~~net~~the ~~revenues~~United States, ~~our~~together ~~gross~~with ~~margin~~associated product, ~~financial~~packaging, ~~condition~~ and ~~results~~freight ofcosts. ~~operations~~The ~~could~~Company beoperates ~~materially~~a ~~and~~capital-light ~~adversely~~production ~~affected.~~model Weusing ~~may~~third-party ~~also~~manufacturers, ~~continue~~co-packers, toand ~~incur~~specialized ~~net~~ingredient ~~losses~~suppliers. inThe ~~the~~Company ~~future~~sources ~~due~~its tospecialized ~~changes~~DAG inoil ~~the~~from ~~macroeconomic~~a ~~and~~strategic ~~regulatory~~manufacturing ~~environment,~~partner ~~competitive~~in ~~dynamics~~China. ~~and~~Due ~~our~~to ~~inability~~the totechnical ~~respond~~nature toof ~~these~~DAG ~~changes~~oil inproduction, asupplier ~~timely~~qualification requires specialized capabilities and ~~effective~~validation ~~manner~~procedures.

~~Our~~16 ~~disclosure~~Table ~~controls~~of ~~& procedures and internal control over financial reporting were ineffective~~Contents

~~Section 404~~Gross ofprofit for the ~~Sarbanes-Oxley~~three ~~Act~~months ofended ~~2002~~December ~~requires~~31, ~~companies~~2025 towas ~~conduct a comprehensive evaluation of their disclosure controls & procedures and internal control over financial reporting. At the end of each fiscal year~~$4,542, wecompared ~~must~~to ~~perform~~a angross ~~evaluation~~loss of ~~our disclosure controls & procedures and internal control over financial reporting~~$2,388 ~~include~~ in ~~our~~the ~~annual~~prior-year ~~report~~quarter. ~~the~~Gross ~~results~~margin offor the ~~evaluation,~~current ~~and~~quarter ~~have~~remained ~~our~~low ~~external~~primarily ~~auditors~~due ~~publicly attest~~ to ~~such~~product ~~evaluation. If material weaknesses were found in our disclosure controls & procedures and internal controls in the future~~mix, ifdistributor wepricing ~~fail to complete future evaluations~~ on ~~time,~~an orinitial ifbulk ~~our external auditors cannot attest to our future evaluations~~order, wefulfillment ~~could fail to meet our regulatory reporting requirements~~ and belogistics ~~subject~~costs, ~~to regulatory scrutiny~~ and athe ~~loss~~impact of ~~public~~operating ~~confidence~~at inrelatively ~~our~~low ~~disclosure~~production and ~~internal~~sales ~~controls~~scale, which ~~could~~limits ~~have~~fixed ancost ~~adverse effect on our stock price~~absorption. In connection with management’s assessment of the Company’s disclosure controls & procedures and internal control over financial reporting, we identified the following material weakness in our disclosure controls & procedures and internal control over financial reporting as of December 31, 2012:

~~Segregation of Duties: We did not maintain adequate segregation of duties related to job responsibilities for initiating~~Selling, ~~authorizing,~~General and ~~recording~~Administrative ~~of certain transactions. Due to this material weakness, there is a risk that a material misstatement in the financial statements would not be prevented or detected on a timely basis.~~Expenses

WeSelling, ~~are~~general ~~subject~~and administrative expenses were $143,296 for the three months ended December 31, 2025, compared to ~~currency~~$12,322 ~~fluctuations~~for the three months ended December 31, ~~which~~2024. ~~may~~The ~~affect~~increase ~~our~~was ~~results~~primarily attributable to higher professional and advisory fees, increased executive compensation, and expanded corporate and compliance costs.

~~The~~During ~~majority~~the ofquarter, ~~our~~the ~~expenses~~Company ~~and~~engaged ~~some~~an ofexternal ~~our~~advisory ~~debt~~firm ~~are~~for incorporate ~~Canadian~~and ~~dollars,~~strategic ~~while~~advisory ~~our~~services ~~revenues~~and ~~are~~recorded ~~primarily~~a ~~U.S.~~one-time ~~dollars~~fee of approximately $32,500. WeThe Company also ~~incur~~incurred consulting expenses inunder ~~Hong~~a ~~Kong~~services ~~dollar~~agreement ~~and~~with ~~Chinese~~a ~~Yuan~~business ~~related~~advisor toat ~~our~~approximately ~~Far~~$2,500 ~~East~~per ~~subsidiaries~~month. ~~The~~In ~~fluctuation~~addition, ofexecutive ~~the~~compensation ~~Canadian~~increased ~~dollar~~during the quarter, ~~Hong~~and ~~Kong~~the ~~dollar~~Company incurred higher legal, accounting, and ~~Chinese~~reporting ~~Yuan~~expenses ~~vis~~associated awith ~~vis~~its ~~the~~corporate Urestructuring and expanded operating activities.S. ~~dollar~~The ~~could~~prior-year ~~materially~~quarter ~~impact~~reflected ~~our~~minimal operating ~~results~~activity and ~~financial~~correspondingly ~~position~~lower overhead costs.

WeNet ~~may be unable to retain key employees or recruit additional qualified personnel.~~Loss

~~Because~~Net ofloss for the ~~specialized~~three ~~scientific~~months ~~nature~~ended ofDecember ~~our~~31, ~~business~~2025 was $138,727, wecompared ~~are~~to ~~highly~~a ~~dependent~~net ~~upon~~loss ~~qualified~~of ~~scientific~~$14,710 ~~technical,~~for ~~and~~the ~~managerial~~three ~~and~~months ~~marketing~~ended ~~personnel.~~December ~~There~~31, is2024. ~~competition~~Although ~~for~~revenue ~~qualified~~increased ~~personnel~~significantly in ~~our~~the ~~business.~~current ~~Therefore~~quarter, wethe ~~may~~Company ~~not~~recorded behigher ~~able~~cost toof ~~attract~~revenues ~~and~~associated ~~retain~~with ~~the~~distributor ~~qualified~~and ~~personnel~~marketplace ~~necessary~~sales ~~for~~and ~~the~~substantially ~~development~~higher ofoperating ~~our business~~expenses. The ~~loss~~increase ofin ~~the~~operating ~~services~~expenses ofwas ~~existing~~driven ~~personnel,~~primarily asby ~~well~~one-time asadvisory ~~the~~fees, ~~failure~~increased toexecutive ~~recruit~~compensation, ~~additional~~and ~~key~~higher ~~scientific~~legal, ~~technical~~accounting, and ~~managerial~~reporting ~~personnel~~costs. inAs a ~~timely~~result, ~~manner~~the ~~would~~increase ~~harm~~in ~~our~~gross ~~research~~profit ~~and~~was ~~development~~more ~~programs~~than ~~and~~offset ~~our~~by ~~business~~higher operating expenses, leading to a larger net loss compared to the prior-year quarter.

27Liquidity and Capital Resources

As of December 31, 2025, the Company had a working capital deficiency of approximately $462,599 and has incurred recurring operating losses. The ~~market~~Company’s ~~price~~operations during the quarter were funded through a combination of ~~our~~product ~~Common~~sales ~~Stock~~and isadvances ~~volatile~~from related parties.

~~The~~Net ~~market~~cash ~~price~~used ofin ~~our~~operating ~~Common~~activities ~~Stock~~for ~~has~~the ~~been,~~three ~~and~~months weended ~~expect~~December ~~it to continue to be~~31, ~~highly~~2025 ~~unstable.~~primarily ~~Factors,~~reflected ~~including~~the ~~our~~net ~~announcement~~loss offor ~~technological~~the ~~improvements~~period, orincreases ~~announcements~~in byinventory ~~other~~associated ~~companies,~~with ~~regulatory~~initial ~~matters,~~distributor ~~research~~stocking and ~~development~~channel ~~activities~~availability, ~~new~~and orpayment ~~existing products or procedures, signing or termination~~ of ~~licensing~~professional ~~agreements, concerns about our financial condition, operating results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights,~~ and ~~public~~advisory ~~concern~~fees. ~~over~~These ~~the~~uses ~~safety~~ of ~~activities~~cash orwere ~~products~~partially ~~have~~offset ~~had~~by aadvances ~~significant~~from ~~impact~~related onparties ~~the~~and ~~market~~increases ~~price~~in ofaccounts ~~our~~payable ~~stock.~~and Weaccrued ~~expect such factors to continue to impact our market price for the foreseeable future~~expenses.

~~Our~~For ~~Common~~the ~~Stock~~three ismonths ~~classified~~ended December 31, 2024, net cash used in operating activities primarily reflected operating expenses and working capital changes, as athe ~~"penny~~Company ~~stock"~~had ~~under~~minimal ~~SEC~~revenue ~~rules~~and ~~which~~lower ~~may~~inventory ~~make~~purchases itduring ~~more~~that ~~difficult~~period. ~~for~~The ~~our~~increase ~~stockholders~~in cash used in operating activities in 2025 compared to ~~resell~~2024 ~~our~~was ~~Common~~primarily ~~Stock~~attributable to higher inventory purchases and operating expenses associated with expanded commercial activity, as well as repayments of $6,280 to related parties during the period.

~~Our~~During ~~Common Stock is traded on~~ the ~~OTC Bulletin Board. As a result~~quarter, the ~~holders~~Company ofincreased ~~our~~finished ~~Common~~goods ~~Stock~~inventory ~~may~~levels ~~find it more difficult~~ to ~~obtain~~support ~~accurate~~distributor ~~quotations~~orders ~~concerning~~and ~~the~~marketplace ~~market value of the stock~~availability. ~~Stockholders~~Management ~~also~~expects ~~may~~inventory ~~experience~~levels ~~greater difficulties in attempting~~ to ~~sell~~fluctuate ~~the~~based ~~stock than if it was listed~~ on adistributor ~~stock exchange or quoted on the Nasdaq National Market or the Nasdaq Small-Cap Market. Because AlphaRx Common Stock is not traded on a stock exchange or on Nasdaq~~demand, and the market price of the Common Stock is less than $5.00 per share, the Common Stock is classified as a "penny stock." Rule 15g-9 of the Securities Exchange Act of 1934 imposes additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as an "established customer" or an "accredited investor." This includes the requirement that a broker-dealer must make a determination that investments in penny stocks are suitable for the customer and must make special disclosures to the customer concerning the risks of penny stocks. Application of the penny stock rules to our Common Stock could adversely affect the market liquidity of the sharestiming, ~~which in turn may affect the ability of holders of our Common Stock to resell the stock. We have a significant number of options~~ and ~~warrants~~logistics ~~outstanding that could be exercised in the future~~planning. Subsequent resales of these and other shares could cause the Company’s stock price to decline. This could also make it more difficult to raise funds at acceptable levels, via future securities offerings.

~~Lack~~The ofCompany ~~Independent~~expects ~~Directors~~that it will need additional capital to support operations, working capital requirements, and business development activities. Management is evaluating financing alternatives, which may include related-party funding, private placements, and other capital raising transactions. There can be no assurance that additional financing will be available on acceptable terms, or at all.

WeThese ~~cannot~~conditions ~~guarantee~~raise ~~that~~substantial ~~our~~doubt ~~Board~~about ~~of Directors will have a majority of independent directors in~~ the ~~future.~~Company’s Inability ~~the~~to ~~absence~~continue ofas a ~~majority~~going ~~of independent directors~~concern, ~~our~~as ~~executive~~discussed ~~officers,~~in ~~which are also principal stockholders and directors, could establish policies and enter into transactions without independent review and approval thereof. This could present~~ the ~~potential~~Going ~~for~~Concern anote ~~conflict~~to ~~of interest between~~ the ~~Company~~condensed ~~and~~consolidated ~~its~~financial ~~stockholders generally and the controlling officers, stockholders or directors~~statements.

~~Ownership~~17 Table of ~~our Common Stock by Current Officers and Directors~~Contents

~~The~~Critical ~~present~~Accounting ~~officers~~Policies and directors own approximately 5.98% of the outstanding shares of Common Stock, and are therefore no longer in a position to elect all of our Directors and otherwise control the Company. As of December 31, 2012, Vago International Limited controlled by Yee Chu beneficially owned approximately 62.90% of our outstanding capital stock. Chu therefore has significant influence over management and affairs and over all matters requiring stockholder approval, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or our assets, for the foreseeable future. This concentrated control limits or severely restricts our stockholders’ ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.Estimates

28The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. A summary of significant accounting policies is included in Note 2 to the condensed consolidated financial statements included in this Quarterly Report.

~~ITEM~~The 2preparation –of ~~UNREGISTERED~~financial ~~SALES~~statements OFin ~~EQUITY~~conformity ~~SECURITIES~~with ~~AND~~U.S. ~~USE~~GAAP OFrequires ~~PROCEEDS~~management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and related disclosures. Management bases its estimates on historical experience and other assumptions it believes to be reasonable under the circumstances. Actual results may differ from these estimates.

WeManagement ~~did~~believes ~~not~~the ~~issue~~most ~~nor~~significant ~~sell~~estimates ~~any~~and ~~equity~~judgments ~~securities~~involve ~~during~~revenue ~~the~~recognition, ~~three~~inventory ~~months~~valuation ~~ended~~and ~~December~~obsolescence 31reserves, ~~2012~~realizability of deferred tax assets, and going concern assessment.

~~ITEM~~Revenue 3Recognition. –Revenue ~~DEFAULTS~~is ~~UPON~~recognized ~~SENIOR~~when ~~SECURITIES~~control of products transfers to customers. Judgments are required in determining the timing of transfer of control, variable consideration, and distributor and marketplace channel terms.

~~Not~~Inventory ~~Applicable~~Valuation. Inventory is stated at the lower of cost or net realizable value. Management evaluates inventory for excess quantities and slow-moving items and records write-downs when necessary based on expected demand and market conditions.

~~ITEM~~Deferred 4Tax –Assets. ~~MINE~~Deferred ~~SAFETY~~tax ~~DISCLOSURES~~assets are reduced by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax assets will not be realized.

~~Not~~Going ~~Applicable~~Concern. Management evaluates whether conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the financial statements are issued and considers plans to mitigate those conditions.

~~ITEM~~Off-Balance 5Sheet ~~– OTHER INFORMATION~~Arrangements

~~Not~~As ~~Applicable~~of December 31, 2025, the Company did not have any off-balance sheet arrangements, as defined in Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future material effect on the Company’s consolidated financial condition, results of operations, liquidity, capital expenditures, or capital resources.

29Recently Issued Accounting Standards

~~ITEM~~Recently 6issued –accounting ~~EXHIBITS~~standards are described in Note 2 to the condensed consolidated financial statements. Management does not expect the adoption of standards not yet effective to have a material impact on the Company’s condensed consolidated financial statements.

(a)		Exhibit index
31.1		Certification of Chief Executive and Interim Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1		Certification of Chief Executive Officer and Interim Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

101.INS **		XBRL Instance Document
101.SCH **		XBRL Taxonomy Extension Schema Document
101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB **		XBRL Taxonomy Extension Label Linkbase Document
101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

The Company is exposed to limited market risk in the ordinary course of its business, primarily related to foreign currency exchange risk and credit risk.

**Foreign ~~XBRL~~Currency (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange ~~Act of 1934, as amended, and otherwise is not subject to liability under these sections.~~Risk

30The Company’s reporting currency is the U.S. dollar. Substantially all revenues and a majority of expenses during the three months ended December 31, 2025 were denominated in U.S. dollars. During the quarter, the Company recorded limited sales and incurred certain expenses through its subsidiaries denominated in Renminbi and Hong Kong dollars.

~~SIGNATURES:~~The Company does not currently use derivative financial instruments or hedging arrangements to manage foreign currency risk. Based on the current level of foreign currency denominated transactions, management does not believe that a hypothetical 10% change in foreign currency exchange rates would have a material impact on the Company’s financial position, results of operations, or cash flows.

~~Pursuant~~18 toTable ~~the requirements~~ of ~~Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Contents

	ALPHARx INC.
DATED: February 22, 2013	By:	/s/ Michael M. Lee
		Michael M. Lee,
		Chief Executive Officer
	Directors:
	By:	/s/ Michael M. Lee
		Michael M. Lee,
		Director
	By:	/s/ David Milroy
		Dr. David Milroy,
		Director
	By:	/s/ Ford Moore
		Dr. Ford Moore,
		Director

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company maintains cash balances with financial institutions it believes to be creditworthy. Accounts receivable arise primarily from marketplace platform settlements and distributor sales. The Company performs ongoing credit evaluations and maintains allowances for expected credit losses when appropriate.

Interest Rate Risk

The Company does not currently have material exposure to interest rate risk, as it does not maintain significant interest-bearing debt or interest-sensitive financial instruments.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, the Company evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December 31, 2025. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of that date due to deficiencies in internal control over financial reporting related to limited accounting personnel and segregation of duties.

Remediation

Management has begun implementing remediation measures to address these control deficiencies, including adding accounting and financial reporting resources, enhancing supervisory review controls, and improving segregation of duties where practical. The Company is also strengthening documentation and period-end review procedures. These remediation efforts are ongoing and will continue to be evaluated and refined.

Changes in Internal Control over Financial Reporting

Other than the remediation activities described above, there were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not a party to any material legal proceedings. From time to time, the Company may be involved in ordinary course claims and matters that arise in the normal course of business. Management does not believe that the resolution of any such matters, if any, would have a material adverse effect on the Company’s financial condition, results of operations, or cash flows.

ITEM 1A. RISK FACTORS

The Company depends on a specialized DAG oil supplier in China. DAG oil production requires technical capabilities and supplier qualification procedures, which limits available sources. A disruption in supply could delay production, increase costs, or reduce product availability.

A single supplier accounted for a substantial majority of the Company’s cost of sales for the quarter ended December 31, 2025. This supplier concentration increases exposure to supply interruption and pricing risk, which could adversely affect margins and operations.

A substantial portion of the Company’s quarterly revenue was derived from a single distributor in China. The Company may not receive future orders from this distributor at similar volumes or pricing levels, and the loss of this distributor or a reduction in its purchases could materially adversely affect the Company’s revenues, cash flows, and results of operations.

The Company relies on third-party manufacturers, co-packers, and logistics providers. Service interruptions, capacity limits, or cost increases at these providers could disrupt fulfillment and increase operating costs.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The Company did not issue any unregistered equity securities during the three months ended December 31, 2025.

No proceeds were received from the sale of equity securities during the quarter.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

The following exhibits are filed as part of this Quarterly Report.

Exhibit No.		Description
31.1		Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer
31.2		Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer
32.1		Section 1350 Certification of principal executive officer
32.2		Section 1350 Certification of principal financial officer
101		Interactive data files pursuant to Rule 405 of Regulation S-T.
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

Table of Contents

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		UMEWORLD INC.

Dated: February 24, 2026		/s/ Michael Lee
		Michael Lee
		CEO, President, and Director
		(Principal Executive Officer)

Dated: February 24, 2026		/s/ Winfield Ding
		Winfield Ding
		Chief Financial Officer
		(Principal Financial and Accounting Officer

Filing Compare · UMeWorld Inc.